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Abstract 
Photodynamic Rejuvenation (PDR) is a novel therapy used to treat the signs of skin ageing. 
It is a promising dermatological therapy due to its less severe side effects and superior 
results when compared to other chemical treatments. This therapy involves the topical 
application of a photosensitizing drug (PS) which is activated by a specific wavelength of 
light to react with oxygen and generate reactive oxygen species (ROS) in the skin. At low 
levels ROS are able to alter cell signalling and are thought to be the key mediators that 
reverse the signs of ageing. Dermatologists use this therapy to treat various characteristics of 
skin ageing such as fine/coarse wrinkles, mottled pigmentation, skin roughness and 
telangiectasia (small broken blood vessels near the surface of the skin). Initial clinical 
reports showed success; however, inconsistencies in patient outcomes provide impetus to 
improve characteristics of current treatment regimes including the PS, light sources, fluences 
and irradiances.  
As very little is known about the actual biological mechanism of PDR in human skin cells, 
the aim of this investigation was to first optimise a protocol using the PS, hypericin, 
activated with 3 different light sources. Hypericin, an extract from St Johns Wort, is a 
second generation PS that has many benefits such as low dark cytotoxicity, no 
carcinogenicity/mutagenicity, high quantum yield and can be activated by several 
wavelengths of light. We chose three light sources that emitted light within hypericin’s 
absorbance spectra: two lasers emitted light at 561nm and 632nm and lamps in a UVA 
transilluminator emitted a light range with a peak at 365nm. Cultured primary human 
fibroblasts were chosen as the cell model as they are an ideal representation of the dermal 
layer of the skin. 
Our results showed that low hypericin concentrations (0.25-0.5µM) at all three wavelengths 
caused an increase in cell viability. When this increase was investigated in relation to growth 
or cellular activity, growth curves showed that PDR with all 3 wavelengths had no effect on 
the cell proliferation rate. To confirm whether ROS was indeed occurring after the therapy, a 
ROS assay was performed. The yellow laser and UVA transilluminator, which emit light 
maximally absorbed by hypericin, were used. UVA served as the upper limit for ROS 
generation as this range of wavelengths is known to cause intracellular ROS. Yellow laser-
activated hypericin resulted in a non-significant increase in intracellular ROS which was less 
than the levels in fibroblasts with UVA activated hypericin. This confirms that PDR using 
hypericin does generate ROS. As migration is considered inverse to collagen production and 
increased collagen is a main objective of skin rejuvenation, we studied fibroblast migration 
after PDR. To assess fibroblast migration in response to yellow laser light activation of 
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hypericin, a scratch assay was used. This PDR protocol showed that migration was 
significantly slowed after treatment. Our proposal is that our PDR protocol with yellow laser 
light decreases migration diverting energy to producing collagen. 
The subcellular location of hypericin closely relates to its mechanism of action in PDR. This 
study showed that hypericin localises to the perinuclear region of the fibroblast and 
colocalizes within the Golgi apparatus with partial colocalization in the mitochondria and 
hardly any with the endoplasmic reticulum. This has not been shown before and gives clues 
as to how hypericin interacts in the cell with our protocol. 
These results characterise the initial cellular response of an optimised PDR protocol using 
the PS hypericin with different wavelengths of light. Future work will involve determining 
the expression levels of several dermal and signalling proteins known to be modulated 
during skin rejuvenation.  
Note: The first part of this work has recently been published (Lasers in medical science epub 
May 12 2012, DOI: 10.1007/s10103-012-1115-2) and the second is currently being prepared 
for submission. 
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1. Chapter 1: Literature Review 
1.1. Introduction 
The skin is the largest organ of the body and its main function is to provide protection from 
the environment. The skin is divided into three layers: the epidermis, dermis and 
hypodermis. The epidermis is the outer most layer and is the first line of defence against any 
insult. The dermis provides the structure of the skin through a framework of interconnected 
proteins known as the extracellular matrix (ECM). The hypodermis is the deepest layer and 
mainly comprises of fat-containing cells. As one ages, characteristics of the skin change 
resulting in - thinning of the epidermis, fine wrinkle development, increased dryness, 
decreased elasticity and overall slower cellular turnover (Gilchrest, 1996). Furthermore, 
there are certain environmental factors that accelerate the ageing process. The most 
prominent factor being chronic UV exposure from sunlight. This type of ageing is also 
known as extrinsic or photoageing (Farage et al., 2008; Gilchrest, 1996). 
Photoageing, in addition to the characteristics of natural ageing, has further distinct 
hallmarks - irregular pigmentation, increased skin roughness, coarse wrinkle development 
and increased small blood vessels near the surface of the skin (telangiectasia) (Avram et al., 
2006; Farage et al., 2008; Gilchrest, 1996). Chronic UV exposure to the skin causes several 
signalling irregularities in the skin that result in these changes (Pillai et al., 2005; Rittié & 
Fisher, 2002). The skin layer most affected by this altered signalling is the dermis. During 
UV exposure, the dermis has an upregulation of ECM degrading enzymes, known as matrix 
metalloproteinases (MMP), and a down regulation of collagen synthesis (Brennan et al., 
2003; Fisher et al., 1996,  1997,  2002,  2008; Pillai et al., 2005; Rittié & Fisher, 2002; 
Talwar et al., 1995). Collagen type I is the main protein in the ECM accounting for 80% of 
its dry weight (Schultz et al., 2005). The damage caused by MMP and the inability to 
generate new collagen results in a broken, structurally comprised ECM of the dermis leading 
to wrinkle formation. The fibroblasts are mechanosensing cells, therefore, decrease tension 
caused by the broken ECM leads to a slowing of cellular metabolism (Varani et al., 2001,  
2006). In addition, repeated exposure of UV to fibroblasts in this already compromised 
situation further exacerbates the signalling changes (Fisher et al., 2009; Varani et al., 2004). 
Overall, the changes result in wrinkle formation among other cellular changes. Coarse 
wrinkles are the most clinically evident sign of chronic UV exposure (Avram et al., 2006). 
There are many treatments available to reverse these signs of skin ageing. Many have shown 
increased collagen synthesis as well as a downregulation of the MMP (Fisher et al., 1996). 
In addition, improvement in skin texture, irregular pigmentation and telangiectasia has also 
been demonstrated (Avram et al., 2006). One such treatment is laser therapy. This therapy 
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uses the ability of certain compound in the skin to absorb light energy. There are many of 
these endogenous compounds, known as chromophores, in the skin that capture light (Peng 
et al. 2008; Waibel 2009). In the case of irregular pigmentation, the pigment melanin is 
targeted and destroyed. Haemoglobin is targeted to destroy small blood vessels thereby 
resolving telangiectasia. This type of therapy has been very successful and its use is wide 
spread (Avram et al., 2006). Stemming from this therapy is a treatment called photodynamic 
rejuvenation (PDR).  
PDR is a relatively new dermatological therapy that has shown great results in reversing the 
signs of skin ageing. It has shown promise as an anti-ageing therapy and numerous in vivo 
studies have shown its positive effects on all signs of photoageing (Bjerring et al., 2009; 
Bruscino et al., 2010; Buggiani et al., 2008; Christiansen et al., 2007; Clementoni et al., 
2010; Dover et al., 2005; Haddad et al., 2011; Kosaka et al., 2010; Orringer et al., 2005; 
Ruiz-Rodriguez & López-Rodriguez, 2006; Ruiz-Rodriguez et al., 2002; Ruiz-Rodríguez et 
al., 2008; Xi et al., 2011; Zane et al., 2007). PDR involves the topical application of a 
photosensitizing drug, or photosensitizer (PS), to the skin and its subsequent activation with 
a specific wavelength of light. A PS has a specific absorbance spectrum that indicates the 
wavelengths of light it maximally absorbs. The wavelength with a highest absorbance will 
result in maximum energy being trapped by the PS causing it to enter a higher energy state 
or become activated. In its activated state it undergoes photochemical reactions and transfers 
its energy to surrounding molecules such as oxygen. Reactive oxygen species (ROS) are the 
most common product (Agostinis et al., 2011; Kiesslich et al., 2006). As mentioned 
previously, ROS can change cellular signalling. The exact molecular mechanism of PDR 
remains largely unknown except for a few preliminary studies (Almeida Issa et al., 2009; 
Choi et al., 2010; Issa et al., 2010; Karrer et al., 2003; Marmur et al., 2005; Orringer et al., 
2005; Park et al., 2010). This led to the purpose of this study to investigate hypericin 
mediated PDR and characterise its in vitro effects on human dermal fibroblasts. 
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1.2. Skin 
The skin is the largest organ in the body and has a number of functions of which protection 
of the body and its internal organs is the most important. The skin is primarily made up of 
three layers viz. the air-facing epidermis, the lower dermis and deep, fat-containing, 
hypodermis.  
The epidermis is a stratified squamous epithelium layer consisting of several cell types and 
is, itself, divided into several strata. The keratinocytes make up the major cell type of this 
epithelium and its proliferative component resides on the basement membrane in a layer 
called the stratum basale. The layers immediately above, called the stratum spinosum and 
granulosum, contain differentiating cells and cells undergoing cell cycle arrest, respectively. 
The uppermost layer comprises of dead cells filled with keratin called the stratum corneum. 
In the stratum basale, there are a small number of other epidermal cells that intersperse the 
keratinocytes such as the pigment-producing melanocytes, immune-responsive Langerhans 
cells and pressure-sensing Merkel cells (Kierszenbaum, 2002a; Young & Heath, 2000). 
Despite the basement membrane originally being touted as an almost “impregnable layer” 
delineating the epidermis from the dermis, we now know that the epidermis and the dermis 
are not distinct independent entities but interact and communicate through paracrine 
mechanisms (Fagot et al., 2002; Ghaffari et al., 2009; Karrer et al., 2004; Maas-Szabowski 
et al., 1999).  
Below the epidermis is the dermis. The main cellular component of this layer is the 
fibroblast. This cell type is important as it produces the majority of the matrix proteins in 
this part of the skin. Together, these proteins provide the structural function of the dermis. 
The framework of this layer, known as the ECM, is composed of several different proteins 
summarised in Table 1.2.1. The dermis provides support for nerves, blood vessels, lymphatic 
vessels and skin appendages such as the hair follicle. 
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Components Proteins  Functions 
Collagen 
• Several different types found 
in the dermis 
• Collagen type I is the most 
prominent in the dermis (80-
85%) with collagen type III 
(8-11%) also being present 
• Rigidity  
• Scaffolding for dermal 
structures 
• Tensile strength 
Elastic Fibres 
• Elastin proteins are at the core 
of the elastin fibres 
• Fibrillin protein surround the 
core of elastic protein and are 
essential for the integrity of 
the elastic fibres 
• Elasticity 
• Resilience  
• Recoil 
Glycosaminoglycan 
(GAGs) 
• Polysaccharide chains with 
amino sugars 
• e.g. Hyaluronic Acid 
• Strongly hydrophilic 
• Trap water molecules 
• Molecule becomes 
swollen 
• Enables the dermis to 
withstand compression 
forces 
Proteoglycans 
• Core protein with GAGs 
attached 
• e.g. Heparan Sulphate 
Decorin 
Perlecan 
• Retain water 
• Allow for movement of 
nutrients, hormones and 
ions 
• Play a role in signalling 
molecules and their 
presentation to the cell 
membrane receptors 
Fibronectin • Glycoprotein 
• Involved with the 
interaction between the 
ECM proteins and cell 
membrane receptors e.g. 
integrins 
• Link different ECM 
proteins 
• Involved in wound 
healing 
Laminin 
• Large protein with 3 
polypeptide chain 
• Cross-shaped molecule 
• The ends of this protein 
bind collagen type IV, 
proteoglycans and 
integrin receptors 
• It is a bridge between 
ECM proteins and the 
basement membrane 
Table 1.2.1 The different dermal proteins that are present in the extracellular matrix (adapted 
from Schultz et al. 2005) 
The fibroblasts attach to the ECM, via integrin receptors, to create tension across the cell. 
This tension in the cell’s cytoskeleton plays an important role in the functioning of the 
fibroblast and is responsible for its classical spindle shape. The integrin receptors are the 
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tethering points for the fibroblasts (Varani et al., 2004; Welch et al., 1990). The receptors 
form part of signalling cascades by communicating extracellular signals into the cell. 
Changes to the tension across the cell, therefore changes to integrin receptors, stimulate 
signalling cascades and ultimately result in altered gene and protein expression (Varani et 
al., 2004). The fibroblasts constantly remodel the proteins of the ECM in response to various 
signals and stimuli through their attachment to the matrix (Fisher et al., 2008; Varani et al., 
2004). Collagen type I is the most abundant protein in the ECM and is secreted by the 
fibroblasts. Collagen type I is integral to the structural integrity of the skin. 
1.2.1. Collagen Type I 
Collagen type I makes up 80% of the dermis’ dry weight (Jenkins, 2002; Schultz et al., 
2005). However, other collagen types are also present in the dermis but to lesser extents. The 
upper papillary dermis consists of fine collagen type I and III fibres whereas the lower 
reticular dermis has thicker bundles of collagen type I as seen in Figure 1.2.1 
 
Figure 1.2.1 A histological section of the skin stained with haematoxylin and eosin 
demonstrating the fine fibres of the papillary dermis (Dp) and the dense bundles of the reticular 
dermis (Dr) (taken from Mine et al) 
Collagen type I is part of a wider family of 16 collagen proteins. A collagen type I fibre 
consists of three protein chains which are bound together by covalent forces. Collagen type I 
is first transcribed from the COL1A1 and COL1A2 genes which produce α1 and α2 peptide 
chains, respectively (Alberts et al., 2002; Kierszenbaum, 2002b). As each collagen protein 
consists of three peptide chains bound together, the individual α chain mRNA transcripts are 
transcribed in various ratios and are specific for the type of collagen protein being produced 
(Alberts et al. 2002). 
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The pre-procollagen peptide chains are translated from the mRNA transcripts by the 
ribosomes and deposited into the endoplasmic reticulum (ER). They have an amino acid 
repeat motif of X-Y-glycine, where X and Y are usually proline and lysine. These amino 
acids are hydroxylated in the ER creating a zipper effect which stabilises a helix formation 
between 3 prepropeptide chains (Lodish et al. 2003; Alberts et al. 2002). This triple helical 
propeptide, is then transported to the Golgi apparatus where it is further processed and 
secreted from the cell into the extracellular space (Figure 1.2.2). The protein, now known as 
procollagen, has its non-helical N and C terminals extracellularly cleaved, resulting in 
tropocollagen (Kierszenbaum, 2002b). Cleavage of these end terminals result in spontaneous 
assembly into collagen fibrils. Cleaved tropocollagens are arranged in a staggered manner 
creating a collagen fibril (Figure 1.2.2) (Alberts et al. 2002).   
 
Figure 1.2.2 A diagram demonstrating collagen gene transcription and protein translation in 
the cell (taken from Alberts et al. 2002) 
The rate of collagen synthesis is determined by fibroblasts in response to various signalling 
molecules, as well as their interaction with the extracellular matrix (Fisher et al., 2008,  
2009; Kierszenbaum, 2002b; Lodish et al., 2003; Varani et al., 2004). This synergy between 
extracellular signals and the environment are what define the metabolism and protein 
synthesis of fibroblasts. The fibroblasts initiate various signalling cascades from their 
mechanosensing interactions with the ECM which control collagen protein synthesis. A 
compromise, therefore, in the structure of collagen fibres, often seen during ageing, will 
result in decreased contact thus decreased fibroblast activity (Varani et al., 2004). As the 
half-life of collagen is 16 years, accumulation of broken fibres over time result in the 
structure of the dermis weakening thus leading to one of the most common signs of ageing, 
wrinkles. 
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1.3. Skin Ageing 
Two types of ageing exist - intrinsic and extrinsic ageing. Intrinsic ageing is non-
pathological, natural process of the skin where changes are not detrimental to the 
functioning of the skin. In contrast, extrinsic ageing is thought to, not only accelerate the 
natural ageing process, but lead to other symptoms such a deep wrinkles, mottled 
pigmentation and the development of small blood vessel near the surface of the skin (known 
as telangiectasia).  
Changes in the skin during ageing occur in both the epidermis and dermis. The dermis has 
the most dramatic changes during both types of ageing. The ECM undergoes severe changes 
resulting in the collapse of the framework thereby compromising the overall structural 
integrity of the skin (Avram et al., 2006; Fisher & Voorhees, 1998; Fisher et al., 2008; 
Gilchrest, 2006; Jenkins, 2002). 
1.3.1. Intrinsic Ageing 
During intrinsic ageing, the skin’s appearance is finely wrinkled, smooth to the touch and 
dry with a loss of elasticity. The overall thickness of the papillary and reticular dermis is 
thinner as it undergoes atrophy. Dermal thinning leading to symptoms of decreased 
resistance and the inability to rebound after tension is applied. The epidermal-dermal ridges 
are also smoother with decreased cellularity which affects wound healing (Farage et al., 
2008; Gilchrest, 1996,  2006). The collagen fibres degenerate, thus, their structure and 
stability within the dermis leads to a comprise resulting in laxity, droopiness and fine 
wrinkles (Farage et al., 2008; Gilchrest, 1996). The inability of the fibroblasts to attach to an 
intact ECM leads to decreased biosynthetic capacity resulting in slower rate of remodelling 
by the fibroblasts in response to stimuli (Varani et al., 2004). Together these events affect 
the skin with regard to mechanical strength, appearance and wound healing.  
1.3.2. Extrinsic Ageing/Photoageing 
Extrinsic ageing is seen as accelerated ageing from exposure to environmental factors – the 
chief being ultraviolet (UV) radiation from sun exposure - this type of ageing is also referred 
to as photoageing. Although it shares many characteristics with intrinsic ageing, other 
symptoms can occur. These signs are often superimposed on intrinsic ageing and 
determining the differences between “normal” intrinsic ageing and “externally-induced” 
extrinsic ageing is very difficult (Gilchrest, 2006; Rittié & Fisher, 2002).  
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Photoageing has been attributed to 90% of cosmetic problems relating to skin ageing 
(Avram et al., 2006). A table describing symptoms of photoageing and associated 
dermatological conditions are shown below in Table 1.3.1. Photoaged skin can have a 
thickened epidermis with possible cellular atypia that may manifest as actinic keratosis as 
well as irregular, mottled pigmentation. Interestingly, the dermis does have distinct extrinsic 
ageing characteristics that set it apart from intrinsically aged skin (Farage et al., 2008; 
Gilchrest, 1996). These characteristics arise from molecular changes caused by UV radiation 
(Callaghan & Wilhelm, 2008; Fisher et al., 2008; Jenkins, 2002; Pillai et al., 2005; Rittié & 
Fisher, 2002). 
 
Table 1.3.1 Characteristics (A)and associated conditions (B) most often seen in photoaged skin 
(adapted from Gold et al., 2006). 
A major histological hallmark of sun exposed skin is the presence of an amorphous mass of 
elastin fibres in the papillary dermis known as solar elastosis. This is caused by UV 
irradiation increasing elastin gene transcription. The skin then appears with a slightly thicker 
looking epidermis and has a yellowish appearance illustrating elastotic degenerative changes 
(Nishimori et al., 1998). 
The upper papillary dermis presents with a severely broken collagen fibre network in 
photoaged skin. These broken fibres are as a result of exposure to UV which led to an 
increase in collagen degrading enzymes (Figure 1.3.1) (Brennan et al., 2003; Brenneisen et 
al., 2002; Callaghan & Wilhelm, 2008; Dong et al., 2008; Fagot et al., 2002; Fisher et al., 
1996,  1997; Jenkins, 2002; Petersen et al., 1992). 
A B 
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Figure 1.3.1 Ultrastructural images of collagen fibres in the dermis. (A) undamaged skin with 
intact collagen fibres (B) represented photoaged skin with broken fibres (taken from Fisher et al., 
2008). 
These enzymes, matrix metalloproteinases (MMP), are a class of zinc coordinate enzymes 
that have specific substrates in the ECM (Page-McCaw et al., 2007). They are present at 
very low levels under normal physiological circumstances, and are only upregulated during 
wound healing (Quan et al., 2009). Table 1.3.2 represents MMP found in the skin and their 
substrates. MMP activity is regulated at three levels: synthesis (primarily transcription), 
activation of the zymogen through cleavage of its prodomain, and inhibition of proteolytic 
activity by tissue inhibitor of metalloproteinases (TIMP) (Page-McCaw et al., 2007).  
MMP  Substrate Alternate name 
MMP-1 Interstitial collagens (types I, II, and III) 
Collagenase-1, interstitial 
collagenase 
MMP-2 Type IV collagen Gelatinase A 
MMP-3 
Fibronectin, Laminin, collagens III, IV, IX, and X, 
and cartilage proteoglycans Stromelysin 1, Progelatinase 
MMP-8 Type I, II and III collagens Neutrophil Elastase 
MMP-9 Type IV and V collagens Gelatinase B 
MMP-10 Proteoglycans and Fibronectin Stromelysin 2 
MMP-13 
Type II collagen and to a lesser extent, types I and 
III Collagenase 3 
MMP-14 Latent MMP-2 protein  Membrane-inserted MMP 
Table 1.3.2 Summary of matrix metalloproteinases (MMPs) and theirs functions (derived from 
Gene Entrez, 2011). 
MMP-1 and MMP-3 are increased in the dermis  after UV irradiation through signalling 
proteins as described later (Brennan et al., 2003; Fisher et al., 1997; Pillai et al., 2005). The 
breaks that result in the collagen fibres are at random locations (Figure 1.3.1) which block 
the regular enzymatic sites and stop clearance of these damaged fibres through regular 
enzymatic methods. UV also causes a decrease in collagen synthesis therefore, if the broken 
fibres are removed, they are not replaced with new fibres (Fisher et al., 2000; Imokawa, 
2009). The collagen fibres are weakened and due to the slow turnover of collagen in the 
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dermis result in a compromised framework and can be referred to as a “Solar scar”. Over 
time the constant weakening will result in wrinkle development (Figure 1.3.2) (Fisher et al., 
1996,  1997,  2008; Imokawa, 2009; Jenkins, 2002). 
 
Figure 1.3.2 Chronic UV exposure to the skin results in the imperfect repair of collagen fibres. 
These fibres cause structural collapse of the skin which is seen as wrinkles (taken from Fisher et 
al., 1997) 
At the cellular level the broken fibres result in the fibroblasts losing their shape and gaining 
a stellate appearance due to the loss in tension (Varani et al., 2001; Welch et al., 1990). As 
mentioned previously (Section 1.2.1), this environment leads to cells decreasing their 
collagen production and increasing MMP production. This highlights the ECM’s influence 
on fibroblast metabolism and that it is not solely dependent on extracellular signals (Fisher 
et al., 2009; Varani et al., 2001,  2004). UV exposure to the skin results in alterations in the 
normal signalling within the fibroblasts and surrounding cells. These changes in the 
molecular pathways, and thus the overall functioning of the cell, result in a situation where 
photoageing signs are exacerbated. 
1.3.3. Signalling Pathways of Extrinsic Ageing 
Photoaged skin has different molecular characteristics compared to intrinsic aged skin (B. A 
Gilchrest 1996; Farage et al. 2008). Photoaged aged skin has reduced levels of antioxidant 
enzymes, high levels of inflammatory cytokines and presence of neutrophils (Pillai et al., 
2005). These changes, both histologically and molecularly, are caused by the skin’s 
exposure to UV radiation from sunlight. 
UV exposure results in an increase in reactive oxygen species (ROS). ROS are known to be 
initiators in normal cell signalling (Thannickal & Fanburg, 2000). However, ROS are 
believed to be the initiators in the signalling cascades that ultimately result in photodamaged 
skin (Brenneisen et al., 1998; Pillai et al., 2005; Rittié & Fisher, 2002). In addition to 
eliciting a signalling response, high levels of ROS can cause damage by oxidising 
biomolecules in the cell i.e. DNA, protein and lipids (Halliwell & Gutteridge, 2007a). Most 
cells have an antioxidant system to protect against ROS by neutralizing their reactive nature 
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(Bickers & Athar, 2006; Rhie et al., 2001). In case of high UV radiation the antioxidant 
system is overwhelmed and ROS drive the signalling response in the skin (Bickers & Athar, 
2006; Brenneisen et al., 1998; Rittié & Fisher, 2002).  
UV exposure to the skin has several effects as summarised in Figure 1.3.3. Immediately after 
the initial ROS, there is an increase in inflammatory cytokines and immune cells. 
Inflammatory proteins and cytokines such as nuclear factor kappa beta (NF-κβ), tumour 
necrosis alpha (TNF-α) and interleukin 1 (IL-1) from activated macrophages and monocytes 
propagate the cell signalling (Meier et al., 1989; Pillai et al., 2005; Wlaschek et al., 1997).  
This results in Mitogen Activated Protein Kinase (MAPK) pathways being activated 
resulting in increased level of c-jun in the epidermal and dermal cells. Together with c-fos, c 
jun forms part of Activator Protein-1 (AP-1) (Fisher & Voorhees, 1998; Fisher et al., 1998,  
2000; Mauviel et al., 1996; Quan et al., 2002,  2010; Verrecchia et al., 2001). This increase 
of AP-1 has two effects on the fibroblasts. The first is an increase in the transcription and 
translation of MMP proteins and the second an inhibition of transforming growth factor-β 
(TGF-β) (Fisher et al., 1998,  2000; Quan et al., 2002) (Figure 1.3.3).  
 
Figure 1.3.3 Signalling mechanism for photoageing with chronic UV exposure insert expanded 
view of AP-1 induction (adapted from Fisher & Voorhees, 1998; Fisher et al., 2008). 
TGF-β is a cytokine that is integral in regulating the proliferation and collagen synthesis in 
fibroblasts (Grotendorst et al., 2004; Ignotz & Massagué, 1986; Leask & Abraham, 2004; 
Varga et al., 1987). TGF-β has been shown to inhibit proteolytic enzyme, such as the MMP 
(Quan et al., 2002). TGF-β, therefore, is associated with maintaining the homeostasis of the 
ECM. UV-induced AP-1 blocks TGF-β and reduces the number of TGF-β receptors on the 
cell resulting in decreased collagen synthesis and increased collagen breakdown resulting in 
a damaged and a structural compromised ECM (Figure 1.3.3) (Chung et al., 1996; Quan et 
al., 2002; Verrecchia et al., 2001). 
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The damage caused by UV exposure over several years, and these processes being 
upregulated time and time again, result in a compromised skin structure. This occurs due to 
an accumulation of MMP-damaged collagen fibres and by the suppression of collagen 
synthesis through the broken ECM environment and activated signalling pathways. Over 
time, these molecular changes result in clinically evident characteristics (as presented in 
Table 1.3.1). To alleviate these often unsightly symptoms, several therapies are used to, not 
only rectify the irregular signalling, but to stimulate the fibroblasts to remove damaged 
fibres and replace it with new collagen proteins. 
1.4. Treatments for Skin Ageing 
There are many regimes and therapies on the market to treat the signs of skin ageing. These 
treatments can be invasive, involving surgery and chemical peels, or non-invasive such as 
topical creams and laser therapies. Invasive methods are used to remove the unsightly skin 
generating a healing response to cause rejuvenation in the skin. Invasive therapies are 
common as the results are generally satisfactory but complications are more severe than the 
non-invasive methods. As individuals heal uniquely, side effects include prolonged 
inflammation, excessive scarring or hyper/hypopigmentation of the specific area (Avram et 
al., 2006). The non-invasive methods are increasing in popularity. Although the outcomes 
are more subtle and usually more than one treatment is needed, these therapies have shown 
to have a comparable effect to invasive therapies (Dierickx & Anderson, 2005; Nestor et al., 
2000). In addition, the benefits tend to be longer-lasting with less associated side-effects. 
One treatment that is popular in society nowadays is laser therapy (Avram et al., 2006; 
Waibel, 2009). 
1.4.1. Laser Therapy 
Techniques such as laser therapy can be both invasive and non-invasive and treat most of 
signs of photoageing. Invasive, or ablative, laser therapy has the same complications as 
surgery and chemical peels. Non-invasive laser therapy can treat a wide range of skin 
conditions such as wrinkles, mottled pigmentation, telangiectasia, purpura, rosacea and 
rough skin texture (Avram et al., 2006; Rinaldi, 2008; Waibel, 2009). This therapy involves 
the use of a laser emitting a specific wavelength of light targeting various compounds or 
cells in the skin (Peng et al., 2008).  
Recent advancements in photonics and optics allowed for the manufacturing of lasers 
emitting numerous wavelengths across the light spectrum. This evolution was to target 
specific organelles and compounds in the cell, such as the mitochondria and porphyrin rings 
in haemoglobin. These compounds capture specific wavelengths of light thereby absorbing 
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their energy. These lasers deliver high levels of energy to either destroy a cell at a specific 
location, as in the case of removing varicose veins, or ablate certain compounds, as is the 
case with the removal of irregular pigmentation. This results in the targeted compound alone 
being destroyed and leaving the surrounding tissue relatively unharmed (Peng et al., 2008; 
Rinaldi, 2008; Waibel, 2009).  
Low doses of light energy to the cells can be stimulated to reduce the signs of ageing and 
resolve other dermatological problems (Dierickx & Anderson, 2005; Rinaldi, 2008; Waibel, 
2009). A threshold between destroying and stimulating cells is a matter of energy, in the 
form of photons, delivered to the skin. If the amount is too high, the energy will scatter 
throughout the tissue causing thermal damage whereas too small an amount will not lead to 
stimulation. 
1.4.1.1. Principle workings of a laser 
Irradiation using a laser is dependent on 3 main variables: energy, power and irradiation 
time. Energy is defined as the ability to cause work and is represented by the unit, Joule (J). 
The energy density or energy per unit area is represented as Joules per square centimetre 
(J/cm
2
). It is also known as fluence, and is the most reported variable when using a laser on 
the skin (Armstrong, 1992). A high dose of energy can lead to side-effects such as purpura 
(red and purple discolouration of the skin), erythema (redness of the skin due to 
inflammation) and oedema (fluid accumulation in the skin) (Waibel, 2009). Indirect damage 
through the generation of high levels of ROS may occur, potentially leading to more serious 
effects (Bickers & Athar, 2006; Mbene et al., 2009). 
Relative to the energy density is the power. It is defined as the rate at which energy is 
delivered and is represented as Watts (W). Power density, otherwise known as irradiance, 
refers to the power in a given area (W/cm
2
) (Armstrong, 1992; Pryor et al., 2011). High 
levels of power or power density have the same effect on cells as high doses of energy. 
These two variables are dependent on one another and involve the time of exposure as seen 
in the equation below (Armstrong, 1992). 
 
Equation 1.4.1 Equation used to determine, energy and power density and exposure time. 
Thus, these three variables are important when using laser therapy and vary greatly when 
treating different skin conditions. In addition, when it is used for the skin, a process known 
as photorejuvenation, there is significant variability in protocols depending on the skin 
condition being treated (Da Silva et al., 2010; Waibel, 2009). 
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1.4.2. Photorejuvenation 
Photorejuvenation is a light therapy used to treat the signs of skin ageing. It changes cell 
signalling pathways to cause an overall rejuvenation effect (Dierickx & Anderson, 2005; 
Lubart et al., 2007). Specific changes are seen such as increased synthesis of collagen and 
upregulation of cytokines that promote repair and maintain ECM homeostasis (Gu et al., 
2011; Huang et al., 2011; Wong et al., 2009). Different light sources and types of light are 
used to stimulate the fibroblasts located in the dermis. There are several different types of 
light sources used in photorejuvenation (Dierickx & Anderson, 2005). 
One of the most common light sources utilized is intense pulsed light (IPL). IPL is a non-
laser, non-coherent, filtered flashlamp emitting high intensity, pulsed, broad bandwidth 
(500 nm – 1200 nm) light (Goldman et al., 2005). IPL is one of the most common light 
sources used to treat photodamaged skin due to its relative inexpensiveness and easy 
application (Goldman et al., 2005). The precise molecular mechanisms of IPL 
photorejuvenation are not known and results vary between patients. An increase of TGF-β  
and collagen type III mRNA and protein were found in fibroblasts irradiated with IPL with a 
570nm cut-off filter with a dose of 75J/cm², highlighting a possible mechanism of 
rejuvenation through TGF-β (Wong et al., 2009). Another article showed that modulation of 
both MMP-1 and TGF-β1 in fibroblasts through MAPKs was light dose dependent when 
using IPL (Huang et al., 2011). 
In recent years the use of a laser for photorejuvenation has become popular due to the 
specificity one gets in manipulating certain variables, such the energy and power density and 
the light beam itself. The table below (Table 1.4.1) summarises lasers that are used in 
photorejuvenation and their emitted wavelengths The wavelengths are related to the targeted 
compound or tissue being treated (Dierickx & Anderson, 2005; Waibel, 2009).  
 
Table 1.4.1 Lasers used in photorejuvenation and the wavelengths of light emitted. CO2 , 
Carbon dioxide; Nd:YAG, Neodymium: Yttrium-aluminium garnet; Er:YAG, erbium: 
Yttrium-aluminium garnet; Alexandrite, alexandrite crystal; PDL, pulsed dye laser; IPL, 
intense pulse laser; KTP, potassium titanyl phosphate (adapted from Waibel 2009). 
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In practice, low level laser irradiation of cells involves using low energy densities by laser 
light to cause changes in the collagen matrix through the stimulation of the resident cells, 
with few side effects (Frigo et al., 2010; Lubart et al., 2007). It is proposed the 
biostimulatory effect of energy delivered by a laser altered the cellular activity. In wound 
healing, red laser light at low fluences resulted in an increase in fibroblasts proliferation and 
an acceleration of wound healing (Hawkins & Abrahamse, 2006; Houreld & Abrahamse, 
2007; Peplow, Chung, & Baxter, 2012a; Rodrigo et al., 2009; Whelan et al., 2001). Due to 
the increase in wavelengths available, photodynamic rejuvenation (PDR) has gained 
momentum as a rejuvenative skin tool as it has been reported to be more effective than 
photorejuvenation alone (Nootheti & Goldman, 2006).  
1.5. Photodynamic Rejuvenation (PDR) 
PDR is a new therapy which involves the use of a topically applied photosensitizer (PS) that 
is activated by a specific wavelength of light in the presence of oxygen to cause alterations 
in cellular metabolism and signalling. It was developed from a therapy of the same principle 
called photodynamic therapy (PDT). PDT was discovered in the 1970s where crude extracts 
of blood containing PS compounds were found to give the skin sensitivity (Allison & Sibata, 
2010). There has been an incredible amount of research in the last few decades for its use in 
the field of dermatology (Kohl et al., 2010; Steinbauer et al., 2010). One of the observations 
noted when using PS to treat benign sun-induced skin lesions, actinic keratoses, was the 
overall improved appearance of the skin (Alexiades-Armenakas & Geronemus, 2003; 
Bruscino et al., 2010; MacGregor & Dover, 2010; Szeimies et al., 2009). This led to the 
development of PDR for the sole use of treating photoaged skin. There are two main 
variables when using PDR: the PS and the activating light source. Both are equally 
important and relate to the efficacy of the treatment.  
PS are integral parts in the efficacy of this treatment. Upon light activation the PS is excited 
from the ground state, S0, to the first excited singlet state, S1, which may be followed by 
fluorescence emission, heat dissipation or yield a triplet state (Kiesslich et al., 2006). Once 
the PS is in the triplet state, it undergoes photochemical reactions where energy is 
transferred to nearby molecules such as oxygen or becomes a free radical itself (Figure 
1.5.1). One of the products of these reactions are ROS (Agostinis et al., 2011; Lubart et al., 
2007) (as described in Figure 1.5.1). ROS are able to alter signalling pathways in the cell 
and cause a release of factors that change the cell’s functionality (Lubart et al., 2007).  
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Figure 1.5.1 Photosensitization process of a PS activated by light. The excited PS moves from 
the ground singlet state (S0) to an excited singlet state (S1). The molecule in S1 may undergo 
intersystem crossing to an excited triplet state (T1) and then either form radicals via type I 
reactions or singlet oxygen from type II reactions. ns indicates nanoseconds; µs, microseconds; 
nm, nanometres; eV, electron volts (taken from Agostinis et al., 2011). 
PS can be divided into two major groups: porphyrins and non-porphyrin photosensitizers 
(O’Connor et al., 2009). Porphyrin molecules possess a highly conjugated, heterocyclic 
macrocycle and may contain a central metallic atom such as iron or magnesium (O’Connor 
et al. 2009). The most common porphyrin PS available today are aminolevulinic acid (ALA) 
and its methyl ester methyl aminolevulinate (MAL). They are precursors in the haem-
biosynthesis pathway and are converted to protoporphyrin IX by ferrochetalase inside the 
cell. ALA itself is not a PS but when converted; its porphyrin product is photoreactive. Non-
porphyrin PS include toluidine blue, methylene blue and hypericin. These compounds do not 
possess a porphyrin ring, but in a similar manner, capture light and can undergo 
photochemical reactions. Each PS has a specific absorbance spectrum which illustrates the 
wavelengths of light captured by this compound resulting in activation. In some cases, the 
PS can be activated by several wavelengths making it a versatile tool when developing a 
therapy to treat specific skin conditions. For example, according to ALA’s absorbance 
spectra, blue light is maximally absorbed. Researchers have found that red light could be 
used for PDR with ALA and was superior to red light alone (Bjerring et al., 2009; Gold et 
al., 2006; Kosaka et al., 2010; Xi et al., 2011). Various light sources are used to activate PS 
and many are similar to those used in photorejuvenation. These include IPL, lasers, normal 
halogen lamps generating white light, and light emitting diode (LED) lamps emitting a 
variety of wavelengths. The light sources chosen depend on the absorbance spectra of the 
PS. A PS might have more than one peak in its absorbance spectra indicating that it can be 
activated by several wavelengths of light.  
Most of the basic science research is in the absorption, distribution, metabolism and 
excretion (ADME) of a PS compound. All of these characteristics play a major part in the 
mechanism of the therapy and its safety. The quantum yield of the PS will indicate the 
amount of energy it can capture and transfer to the surrounding molecules. The higher the 
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quantum yield, the less PS will be needed to generate ROS and other reactive species. This 
leads to fewer side-effects occurring from phototoxic reactions. 
There have been numerous clinical studies showing the range of cosmetic improvements that 
can be achieved with PDR. Various PS, light sources and activating wavelengths were used; 
all show an improvement in an aspect of skin rejuvenation. These reports were summarised 
in Table 1.5.1 and Table 1.5.2. 
1.5.1. Summary of Clinical Reports using PDR 
Table 1.5.1 was compiled to illustrate the variety of clinical data in the literature regarding 
study design, applications, outcomes and side effects of photodynamic rejuvenation.  
The sample sizes in the clinical studies varied in range from 7 to 37 subjects and were 
generally quite small. Overall patient group size had a mean of 26 per study.  
The patients were in the 5
th
 to 7
th
 decade of life for over half the studies. This is in line with 
the development of photoageing being in the later years of life. Most studies were conducted 
on patients who had lighter skin tones and were grouped in Fitzpatrick’s scale I-III. This 
correlates with lighter skin types being more prone to develop skin ageing characteristics 
therefore in need of intervention (Farage et al., 2008; Rawlings, 2006).  
The longer wavelengths of light were chosen as they can penetrate deep into the dermal 
layer and potentially activate the PS within that area. There was a trend of 37J/cm
2
 energy 
density used for these in vivo studies. Although, a range of energy densities (4-96J/cm
2
) 
were used. The high energy densities resulted in an increased severity of adverse side-effects 
such as erythema, oedema and crusting. It was common that authors did not mention the 
power density.  
IPL is the most common light source used in PDR. IPL emits a wide range of wavelengths 
(550nm-1200nm) and is often used with a cut-off filter which limits the range mainly to the 
red light spectrum. Red light is also emitted from LED. The IPL and LED systems are 
commonly used in dermatological clinics for photorejuvenation; therefore, their use with 
PDR makes them a viable and cost effective option.  
The most common PS used in PDR are ALA and MAL. This is due to their easy availability 
as licenced drugs in both the United States of America and Europe. ALA is provided as a 
20% solution, however researchers used lower concentrations. Kosaka et al, for example, 
investigated the differences in fluorescence in skin using different concentration of ALA 
(Kosaka et al., 2010). They found that 5% ALA concentration had a similar fluorescence to 
the higher concentrations. ALA is prescribed to be applied 14-18h before light activation 
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according to the manufacturer’s instructions. Shorter incubation times were employed in 
some studies and resulted in similar outcomes compared to the longer incubation periods, 
and with less severe side effects (Bjerring et al., 2009; Christiansen et al., 2007). In the 
majority of the cases a 3 hour incubation of the PS was used. Another aspect was to 
investigate improving the manner in which a PS was applied to the face and suggested 
microneedling, tape stripping and dermabrasion in order to increase its penetration and 
thereby increasing its efficacy (Clementoni et al., 2010; Lowe & Lowe, 2005).  
Another interesting variable were the number of treatments applied and intervals between 
them. The number of treatments did not exceed three and in most cases these were separated 
by 30 days intervals. One study debated whether more treatments with lower concentration 
of PS and shorter incubation times and lower energy densities gains superior results as 
opposed to one treatment with higher concentrations, longer incubations times and increased 
energy densities (Xi et al., 2011). A high PS concentration and energy density is a harsh 
PDR protocol that may result in severe reactions and more pronounced side effects. In 
contrast a “softer” protocol, using low concentrations of PS and energy densities, would 
result in a subtle and gradual improvement in the signs of skin ageing (Xi et al., 2011). 
In performing this therapy, the PS was either applied to the entire face or only half the face, 
known as a split-faced study. The split-faced studies determined if the light alone had an 
effect on the skin. In some cases, actinic keratoses were specifically investigated as a sign of 
photodamage and the PS was only applied to the lesional area. However, in these studies, the 
authors retrospectively commented on the overall good cosmetic appearance of the skin after 
treatment (Alexiades-Armenakas & Geronemus, 2003; Bruscino et al., 2010)(Ruiz-
Rodriguez et al., 2002). The follow up period for the studies was generally between 1 and 6 
months after the last treatment. One or two follow up consultations took place where the 
investigator either took photographs or biopsies.  
Various methods were used to assess the efficacy of PDR. The most commonly used were 
photographs taken before the start of the study and at follow ups. These photographs were 
either analysed by the investigator or by an independent clinician. In a large portion of 
studies, each individual characteristic of photoageing was assessed and graded. In most 
cases a point scale system was used to investigate mottled pigmentation, sallowness, 
telangiectasia, roughness, fine lines/wrinkles, deep wrinkles and global photoageing. Fine 
lines or wrinkles, mottled pigmentation, sallowness and tactile roughness of the skin were 
often improved. Interestingly, telangiectasia and coarse lines/wrinkles were often not 
improved with PDR treatment. In split-faced studies, the PDR treated side had better results 
than the light only control (Bjerring et al., 2009; Gold et al., 2006; Kosaka et al., 2010; 
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Nootheti & Goldman, 2006; Xi et al., 2011). In studies which took into account the patient’s 
observations, a high patient satisfaction was noted.  
Interestingly, the information gleaned from Table 1.5.1 indicates that no clear “gold 
standard” protocol exists for using PDR. Variables include different ethnic populations, 
different outcomes, patient education and skin tone. In addition, the disparity between 
protocols and assessment methods makes it difficult to effectively compare these studies 
(MacGregor & Dover, 2010). However, a cross comparison such as this has not been 
attempted before and sheds valuable light on the field of PDR. 
Overall, the outcome of PDR on the photoageing was satisfactory for both the patients and 
clinicians. Although the studies were generally quite small, the rejuvenative power of PDR 
was seen throughout. The phototoxic reactions that occurred when using PDR were 
temporary and side effects were resolved within 7 days with no further complications 
experienced. Interestingly, the inconsistencies in outcomes seen in Table 1.5.1 were possibly 
due to the different patients, the type and application of the PS, light sources, irradiation 
protocol, and the individual patient’s response to the therapy. However, this therapy was 
never detrimental to the health of the patient and the appearance of the skin never worsened 
because of it. Some pain management was needed during the treatment but overall it was 
well tolerated. This therapy has shown great promise in treating photoageing especially in 
the categories of mottled pigmentation, skin roughness and fine wrinkles. 
1.5.2. Summary of Molecular Reports using PDR 
The molecular mechanisms behind PDR have only recently been investigated and are 
presented in Table 1.5.2. Researchers, using pathways established from other anti-ageing 
therapies, investigated certain downstream effectors and determined their modulation after 
PDR.  
In a variety of studies, the models used to determine the molecular mechanism of PDR were 
human, mice and single cultured cell types. These models allowed the researchers to 
examine several effects of PDR under controlled conditions. For examples, primary 
fibroblasts and keratinocytes were used in most cases as they are the two main skin cell 
types affected and they communicate extensively with one another (Fagot et al., 2002; 
Ghaffari et al., 2009; Karrer et al., 2004; Maas-Szabowski et al., 1999). The researchers 
investigated the specific reactions of these cells after treatment. ALA and MAL were used in 
the majority of the molecular studies. The concentration and incubation times of the PS 
differed between experimental models. For example, in vitro experiments using primary 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1: Literature Review 
 
20 
 
fibroblasts were treated for 24h compared to the in vivo studies using humans and mice 
where the incubation time was 3h (Karrer et al., 2003) (Table 1.5.1).  
IPL, PDL and lamps were the most common light sources used and the most common 
wavelengths were in the red range. The energy densities delivered from these light sources 
range from very low (7.5J/cm
2
) to very high values (100J/cm
2
). The power density was kept 
in the low range of 35-100mW/cm
2
.  
Interestingly, a single PDR treatment was used on primary cells whereas patients were 
treated several times in accordance with previous clinical protocols (Table 1.5.1). 
Accordingly, follow up times varied as many studies focused more on immediate changes 
whereas patient-driven studies were days or weeks after PDR treatment.  
The outcomes of PDR were analysed by investigating changes in mRNA and protein 
expression levels and enzyme activity. Various assays were employed for these analyses: 
RT-PCR for gene expression analysis; western blot analysis, ELISA and 
immunohistochemistry for protein expression; and zymography for enzyme activity.  
The effect of PDR treatment on collagen type I expression seemed to be time dependent 
(Choi et al., 2010; Orringer et al., 2005) (Table 1.5.2). Using RT-PCR, Karrer et al found 
collagen type I mRNA to be decreased 24h after treatment returning to basal levels after 72h 
(Karrer et al., 2003). Analyses of later time points in different studies, showed collagen 
mRNA and protein levels increased after 16 days (mice) and from 1 to 6 months (humans). 
Overall, it appears that collagen synthesis is initially decreased by PDR and increases at later 
time points.  
MMP are enzymes that selectively breakdown the ECM. It is thought that an increase in 
MMP levels in PDR remove the damaged collagen fibres thereby stimulating collagen 
synthesis in the fibroblasts. A variety of MMP enzymes were investigated. MMP levels 
showed an inverse correlation to collagen levels, where there was an early increase in all the 
experimental models used. MMP-1 mRNA and protein consistently displayed an immediate 
increase post-PDR treatment. Other MMP’s in the family, such as MMP-3, MMP-2 and 
MMP-9, in both in vivo and in vitro studies, had a similar response as MMP-1 and all 
returned to basal levels a few days later. 
TGF-β is a major regulator of collagen homeostasis (Section 1.3.3). However, there have 
been limited studies investigating TGF-β after PDR. Park et al found that TGF-β and its 
receptor were increased in the epidermis one month after treatment (Park et al., 2010). Choi 
et al found that TGF-β1 mRNA increased 2 days after PDR in mice (Choi et al., 2010). 
However, from this data we cannot draw a conclusion as on PDR’s effect on TGF-β.  
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The overall picture after analyses and summary of these two tables demonstrate a lack of 
consistency and information regarding PDR treatment. However, these tables illustrate the 
data available and represent the information contributed to this field and that which still 
needs to be discovered. The overview from the reported results indicates that PDR is a 
useful tool for the treatment of photoaged skin although an optimised protocol still needs to 
be established. As such, the aim of this project was to develop a PDR protocol using a PS 
from the extract of the Hypericum perforatum plant, commonly known as St Johns Wort. 
We used this PS in a novel way in its development for PDR and determined its effects on 
primary human dermal fibroblasts. 
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Reference 
No. of 
Patients 
PS & 
concentration 
PS 
incubation 
period  
Wavelength of 
Light 
Light 
Source 
Energy/ 
Energy 
Density 
Power/ 
Power 
Density 
No. of 
Follow 
up 
Follow up 
time  
No. of 
treat-
ments 
Intervals 
between 
treat-
ments Application Assessment method Comment Side Effects 
(Ruiz-
Rodriguez 
et al., 2002) 17 20% ALA  4h 
Non-coherent 
light filtered - 
590 to 1200 nm IPL  40 J/cm2 N/A 
Full-
face 
1 and 3 
months 2 1 month 
 AK lesional 
area treated Author commentary 
Cosmetic appearance improved 
drastically 
Erythema, oedema, 
crusting 
(Alexiades-
Armenakas 
& 
Geronemus, 
2003) 
41 
(Mean 
age 70 
years) 20% ALA 
3h under 
occlusion 
or 4-18h 
not 
occluded 
595nm (pulsed 
light) PDL 4-7.5J/cm2 N/A 5 
10 days, 2, 4, 
6 and 8 
months 1 0 
Full face 
application 
Biopsies and 
photographs were 
taken 
No difference between the 3h 
and 14-18h incubation times 
regarding efficacy. PDL light 
only had no effect on AK lesions 
after 1 month. Excellent post 
treatment cosmesis was noted 
and was seen as a major 
advantage of this treatment over 
other treatments for AKs. 
including stinging, 
burning, erythema, 
and pain were 
recorded 
(Touma et 
al., 2004) 
18 
(Ages 
41 - 76 
years) ALA 1,2 and 3h Blue 
Fluo-
rescent 
tubes 10J/cm2 N/A 0 
1 day, 1 
week and 1 
month, 10 
patients for 6 
month follow 
up 1 0 
Full face 
ALA 
treatment 
with split 
faced for 
creams 
applied 
before the 
ALA 
treatment 
(vehicle vs. 
40% urea 
cream) 
8-point Griffiths 
score index and 
patient and 
investigator 
evaluations. 
Great improvement with regard 
to sallowness and fine lines and 
mild improvement on mottled 
pigmentation. Patient satisfaction 
was high with 76% of patients 
noting a good response to the 
treatment. Neither ALA 
incubation time had no effect nor 
did 40% urea cream pre-
treatment result in significant 
differences regarding 
photoageing or side effects.  
Erythema and 
oedema were noted 
to be moderate to 
severe 1 day after 
treatment. At 1 
month after 
treatment most of 
the side effects has 
resolved. Most 
patients had no 
crusting. 
(Lowe & 
Lowe, 
2005) 
6 
patients 5% ALA  30 min 633nm LED 96 J/cm2 
105 
mW/cm2 1 
Only before 
and 4 weeks 
after 
treatment 
were 
reported for 
photoageing. 1 0 
Stripping 
with tape 
Clinical assessment 
using photographs 
and a grading 
system. Grading 
was done according 
to the Glogau 
grading scale. 
(Glogau, 1996) 
Significant improvement in the 
periorbital region with a 
reduction in fine lines in 67% of 
the patients.  
Treatment was 
tolerated well and 
no adverse side 
effects were noted, 
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Reference 
No. of 
Patients 
PS & 
concentration 
PS 
incubation 
period  
Wavelengt
h of Light 
Light 
Source 
Energy/ 
Energy 
Density 
Power/ 
Power 
Density 
No. of 
Follow 
up 
Follow up 
time  
No. of 
treat-
ments 
Intervals 
between 
treat-
ments Application 
Assessment 
method Comment Side Effects 
(Dover et al., 
2005) 
20 (White, 
mean age: 
55 years) ALA  30-60min 
515-
1200nm IPL 23-28J/cm2 N/A 
Full-
face 4 weeks 5 3 weeks 
 3 ALA-IPL 
treatments 
and 2 IPL 
alone 
treatments 
Independent 
investigator who 
assessed fine 
lines, mottled 
pigmentation, 
tactile roughness, 
sallowness, and a  
global score for 
photoageing 
using a 5 point 
scale system. 
The greatest results were in mottled 
hyperpigmentation and global 
photoageing, and to a slightly lesser 
extent, in fine lines over IPL 
irradiation only. However, areas like 
sallowness and tactile roughness did 
not show any improvement. The 
authors comment on the possible 
accelerated improvements when the 
skin was pretreated with ALA. 
Erythema, 
scaling, dryness 
and oedema but 
were reported to 
be minimal 
(Gold et al., 
2006) 16 ALA  30-60min 
515-
1200nm 
with 
550nm 
cut-off 
filter IPL 34J/cm2 N/A 2 
1 and 3 
months 3 1 month Split-faced 
Blinded 
independent 
investigator assed 
tactile roughness, 
crow’s feet 
appearance, 
mottled 
pigmentation, 
facial 
telangiectasia, 
and facial AKs 
via a graded 
scale. 
In all areas -Crow’s feet, tactile skin 
roughness, mottled 
hyperpigmentation, telangiectasia and 
actinic keratoses improvement was 
greater in the ALA pretreated side 
compared to the IPL only treated  
Erythema and 
oedema were 
seen in fewer 
than 10% of the 
treatments and 
were noted on 
both sides of the 
face. 
(Ruiz-
Rodriguez & 
López-
Rodriguez, 
2006) 10 MAL 1 and 3h 630nm LED 37J/cm2  N?A 1 2 weeks 3  N/A Split-faced 
Reported by the 
author  
3hr incubation showed superior 
results to 1hr incubation. Skin quality 
and fine wrinkles ad improved but 
not telangiectasia or mottled 
pigmentation. Compared different 
light sources in PDR. 
3hr incubation 
had more severe 
erythema, 
oedema and 
crusting 
(Zane et al., 
2007) 
20 (White; 
Mean age 
of 68.9 
years) ALA 3h Red LED 37J/cm2  N?A 2 
At second 
treatment and 
2 months 
after last 
treatment 2 1 month Full face 
Photoageing was 
quantified using a 
five point scale. 
A global score 
was recorded in 
addition: fine 
periocular lines, 
mottled 
pigmentation, 
sallowness, and 
tactile roughness. 
Significant improvement in the 
following signs of photoageing: 
global ageing, fine lines, mottled 
pigmentation, sallowness and 
roughness. Deep wrinkles, 
telangiectasia,  
facial erythema, and sebaceous gland 
hypertrophy did not show any 
improvement. Most patients were 
very satisfied with the treatment 
(12/18 patients). 
erythema and 
oedema which 
only lasted for 3 
days  
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Reference 
No. of 
Patients 
PS & 
concentration 
PS 
incubation 
period  
Wavelength 
of Light 
Light 
Source 
Energy/ 
Energy 
Density 
Power/ 
Power 
Density 
No. of 
Follow 
up 
Follow up 
time  
No. of 
treat-
ments 
Intervals 
between 
treat-
ments Application 
Assessment 
method Comment Side Effects 
(Buggiani et 
al., 2008) 25 5% ALA  3h 636nm Lamp N/A N/A 2 
2 weeks after 
first 
treatment, at 
the end of the 
last treatment. 3 I month 
Prepared the 
skin with 
glycolic acid 
or pirutic 
acid. Full 
face 
application 
Observation from 
investigator and 
OCT 
Observed improvements in mottled 
pigmentation and skin texture but not 
in wrinkles or telangiectasia.  Using 
OCT the epido-dermal junction 
became undulating from a relatively 
straight junction. At the end of the 
last treatment 70% had improvement 
regarding skin texture. N/A 
(Ruiz-
Rodríguez et 
al., 2008) 
10 (White, 
mean age: 
55 years) MAL 1 and 3h 630nm LED 37J/cm2  N/A 1 2 months 3 2 weeks Split-faced 
Blinded 
independent 
investigator 
Improvement in the skin was only 
seen with the 3 hour incubation in the 
categories of skin tightness and fine 
wrinkles. None of the other signs 
showed the improvement that was 
seen in early studies. 
3hr incubation had 
more severe 
erythema, oedema 
and crusting 
(Szeimies et 
al., 2009) 131 
160mg/g 
MAL 3h 630nm LED 37J/cm2 
56-
83mW/c
m2 2 
2 weeks and 3 
months 2 1 week Full face 
Independent 
clinician noted 
the resolution of 
AK lesions 
AK were significantly decreased at 3 
months along with excellent cosmetic 
results. Authors suggest PDR when 
cosmesis is a high priority when 
treated AK, i.e. when AK are present 
on the face. 
Pain, burning and 
erythema were 
common and were 
resolved within 
several days 
(Kosaka et 
al., 2010) 
5 
(Japanese, 
mean age: 
36 years) 5% ALA  2h 
515-
1200nm IPL 
23–30 
J⁄cm2  N/A 2 
1 and 3 
months 3 1 month Split-faced 
Independent 
investigator using 
a 5 point scale 
assessment for 
mottled 
pigmentation, 
crow’s feet 
appearance, fine 
lines, tactile 
roughness and 
sallowness were 
evaluated as 
indexes of 
photodamage. 
Improvement in all areas but it was 
found that there was no significant 
difference between IPL using ALA 
and IPL alone however; IPL using 
ALA was tending to has superior 
effects. 
The authors 
suggest that due to 
the darker skin 
type of the 
patients the side-
effects were more 
pronounced and 
last longer. 
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Reference 
No. of 
Patients 
PS & 
concentration 
PS 
incubation 
period  
Wavelength 
of Light 
Light 
Source 
Energy/ 
Energy 
Density 
Power/ 
Power 
Density 
No. of 
Follow 
up 
Follow up 
time  
No. of 
treat-
ments 
Intervals 
between 
treat-
ments Application 
Assessment 
method Comment Side Effects 
(Clementoni 
et al., 2010) 
21 patients 
(White; 
Mean age: 
56 years) ALA 1h 
(1) 550nm-
1200nm; 
560nmcut-
off filter; 
(2) 630nm 
(1) IPL; 
(2) LED 
19–22 
J/cm2  N/A 2 3-6 months 1 0 
Microneedlin
g followed 
by ALA. Full 
faced. 
Treatment 
with LED 
after IPL. 
Three physicians 
used the 5-point 
scale for the 
categories: fine 
lines, mottled 
pigmentation, 
sallow 
complexion, 
tactile rough- 
ness, 
telangiectasia, 
and coarse 
wrinkles 
A statistical difference was present 
between 3 and 6 months for global 
score, fine lines, sallowness and 
tactile roughness. No statistical 
differences were seen between 3 and 
6 months after the treatment for 
mottled hyperpigmentation and 
telangiectasia. At 3 and 6 months 
after the treatment, coarse wrinkles 
showed no statistical significance 
compared to the baseline. 
Erythema, oedema 
and crusting were 
noted 1 day after 
the treatment and 
were resolved by 
day 7. No pain 
management was 
necessary. 
(Bruscino et 
al., 2010) 
1 (Italian 
female 88 
years old) 
160mg/g 
MAL 3h 632nm Lamp 37J/cm2 
70-
100mW/
cm2 1 1 month 1 0 
Applied to 
lesional area 
Photography and 
3D-profilometry 
Significant reduction in wrinkle 
depth one month after treatment 
through 3D profilometry 
Burning, crusting 
and pain 7 days 
after treatment 
(Sanclemente 
et al., 2011) 
48 
females. 
Mean age: 
51.5 year 0.5g MAL 3h Red N/A 37J/cm2 N/A 2 
1 month 
after 2 
treatment 
and 1 month 
after the last 
treatment 4 
2-3 
weeks 
Split-faced 
where one 
side was 
treated with 
PDT and the 
other had 
light only. 
Independent, 
blind investigator 
Improvement in the MAL activated 
by light in the following areas: global 
photoageing signs, fine and coarse 
lines, mottled pigmentation, tactile 
roughness and sallowness 
The PDT treated 
side experienced: 
more pain and 
desquamation vs. 
placebo, erythema 
was frequent, 
oozing was noted. 
Pigmentation 
occurred and was 
resolved within a 
few days.  
(Haddad et 
al., 2011) 21 ALA  2h 
500 to 
1200nm 
with a 515-
nm filter IPL 
20, 25, 40, 
and 50 
J/cm2 N/A 2 
5–7 days and 
8 weeks 1 0 Full face 
Photodamage 
severity was 
determined by 
the 9-point 
photonumeric 
Griffiths scale. 
Increasing fluence did not 
significantly change the results 
regarding resolution of photoageing 
signs. However, the majority of 
patients did note an improvement 
overall and ALA pretreatment had 
superior results compared to IPL 
alone. 
Erythema, 
oedema, crusts and 
erosion, and pain 
occurred. Graded 
on a 5-point scale. 
The higher the 
fluence resulted in 
more severe side 
effects. 
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Reference 
No. of 
Patients PS & conc 
PS 
incubation 
period  
Wavelength 
of Light 
Light 
Source 
Energy/ 
Energy 
Density 
Power/ 
Power 
Density 
No. of 
Follow 
up 
Follow up 
time  
No. of 
treat-
ments 
Intervals 
between 
treat-
ments Application 
Assessment 
method Comment Side Effects 
(Rossi, 2011) 
25 
(Female) ALA N/A 632nm Lamp 37J/cm2` 
70-
100mW/
cm2 1 3 months 3 1 month Full face 
Investigator 
observations and 
optical coherence 
tomography 
(OTC) 
Saw improvement in mottled 
pigmentation and skin roughness. 
Improvement in the epido-dermal 
junction ridges from baseline 
readings. N/A 
(Xi et al., 
2011) 
24 
patients; 
mean age: 
48 year, 
Dark skin 
tone 5-10% ALA 1h 
550nm-
1200nm 
(590nm cut-
off filter) IPL 14-21J/cm2 N/A 2 
1 and 2 
months 3 1 month Split-face 
An independent 
investigator 
monitored and 
graded global 
photoageing, 
tactile skin 
roughness, fine 
lines, coarse 
wrinkles, and 
mottled 
hyperpigmentatio
n 
PDR results in global photoageing 
score, fine lines, and coarse wrinkles 
showed superior improvement 
compared to IPL alone treatment. 
Side effects were 
more severe in the 
ALA pretreated 
side regarding 
erythema and 
oedema. Post 
inflammatory 
hyperpigmentation 
occurred 
transiently and 
faded within 2 
month. 
Table 1.5.1 Sumamry of clinical studies that used PDR. AK: Actinic Keratosis/Keratoses; IPL: intense pulsed light, N/A: information not available; conc: concentration 
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Reference 
No. of 
Patients PS & conc 
PS 
incubation 
period  
Wavelength 
of Light 
Light 
Source 
Energy/ 
Energy 
Density 
Power/ 
Power 
Density 
No. of 
Follow 
up 
Follow up 
time  
No. of 
treatm
ents 
Intervals 
between 
treatments Application 
Assessment 
method Comment Side Effects 
(Karrer et 
al., 2003) 
Normal 
and 
scleroderm
a primary 
human 
fibroblasts ALA 24h 
580nm-
740nm 
Halogen 
Lamp 24J/cm2 
40mW/ 
cm2 
Depen
dent 
on 
assay 
used 
0, 4, 6, 12, 
24, 48, and 
72 h 1 0 
Collagen 
lattice with 
fibroblasts 
were treated 
with medium 
containing 
ALA 
XTT cell 
viability, ELISA 
and RT-PCR 
In normal human fibroblasts mRNA 
levels of MMP-1 and MMP-3were 
increased as early as 4 hours but after 
24 hours had almost returned to basal 
levels. It was found that MMP-1 and 
MMP-3 protein and activity were 
increased in normal human 
fibroblasts over a period of 48 hours 
thereafter began to decrease. 
Collagen type I mRNA significantly 
decreases for up to 24 hours  N/A 
(Karrer et 
al., 2004) 
Fibroblasts 
and 
Keratinocy
tes 
100µmol/l 
ALA 24h 
580nm-
740nm 
Halogen 
Lamp 24J/cm2 
40mW/c
m2 
Depen
dent 
on 
assay 
used 6–48 h 1 0 
Conditioned 
medium from 
PDR treated 
keratinocytes 
was used on 
the 
fibroblasts 
XTT cell 
viability, ELISA 
and RT-PCR 
Conditioned medium from 
keratinocytes 24h after PDR 
stimulated fibroblasts to increase the 
protein levels of MMP-1 and 3 48h 
later. However, after 96h the levels 
returned to normal. Collagen type I 
RNA was not altered after 
conditioned medium was placed on 
the cells. Collagen IV coated 
transwell were used where 
keratinocytes were on one side and 
fibroblasts on the other. Only small 
molecules can pass through the 
transwell. Induction of MMP-1 and 3 
was only noted on the supernatants 
from the fibroblasts and not the 
keratinocytes. IL-1RA completely 
abrogated the stimulation of 
fibroblasts from the keratinocyte 
conditioned medium. N/A 
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Reference 
No. of 
Patients PS & conc 
PS 
incubation 
period  
Wavelength 
of Light 
Light 
Source 
Energy/ 
Energy 
Density 
Power/ 
Power 
Density 
No. of 
Follow 
up 
Follow up 
time  
No. of 
treatm
ents 
Intervals 
between 
treatments Application 
Assessment 
method Comment Side Effects 
(Marmur et 
al., 2005) 
7 patients; 
Mean age: 
51 years ALA 1h 
550-
1200nm 
with 550nm 
cut-off 
filter IPL 24J/cm2 N/A 1 3 month 2 1 month Split-faced 
Dependent 
investigators. 
Punch biopsies 
were also taken 3 
months after 
treatment for 
electron 
microscopy. 
Greater shift towards collagen type I 
production than collagen type III and 
had an increase in fibre number. 
Increase in collagen type I in ALA-
IPL treated cells could be due to the 
thermal effects of IPL and the ROS-
generating reaction of activated ALA. 
It was noted that there was a 
subjective improvement in the skin 
overall however, there was no 
difference between those treated with 
IPL or with IPL and ALA.  
No mottled 
pigmentation, 
blistering, or 
crusting occurred. 
Transient, mild 
erythema and 
burning occurred 
on both sides on 
the face and was 
resolved within 
24 hours. 
(Orringer 
et al., 
2008) 
24 
patients; 
All 
patients 
over the 
age of 40 
years. 
Mean age: 
68 years 20% ALA  3hr 595nm PDL 7.5J/cm2 N/A 4-5 
Up to 6 
months 1 0 Forearm skin 
RT-PCR, 
immunohistoche
mistry (IHC). 
3mm punch 
biopsies taken. 
MMP-1 gene expression increased 
20-fold and returned to basal levels 
within 24 hours. Prolyl-4-
hydroxylase, an enzyme involved in 
post-translation modification of 
collagen, was elevated 3-fold one 
month after treatment. RT-PCR 
results indicated that collagen type I 
and III mRNA levels were 
significantly increased after 30 days. 
Procollagen type I and III mRNA 
peaked at 30 days and decreased, but 
not to basal levels. 
Procedure well 
tolerated. 
Erythema and 
focal crusting 
was noted after 
treatment. 
(Almeida 
Issa et al., 
2009) 
14 Patients 
aged 55-60 
years; 
Mean age: 
57.6 years MAL 2h 635nm LED 37J/cm2 N/A 2 
3 and 6 
months 2 4 weeks Full face 
Biopsies were 
taken for 
histology and 
(IHC) results 
were examined 
by three 
independent 
observers. 
At 3 months - Elastotic material 
becomes more diffuse and collagen 
appears between the elastic fibres. 
MMP-9 and collagen type I. IHC 
staining was moderately increased 
from before treatment. At 6 months - 
Collagen fibres increased further 
between the elastotic fibres and a 
band of collagen was noted in the 
upper papillary dermis in some 
patients. Fragmented elastic fibres 
were decreased substantially and 
there was a stronger staining for 
collagen type I compared to 3 
months. N/A 
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Reference 
No. of 
Patients PS & conc 
PS 
incubation 
period  
Wavelength 
of Light 
Light 
Source 
Energy/ 
Energy 
Density 
Power/ 
Power 
Density 
No. of 
Follow 
up 
Follow up 
time  
No. of 
treatm
ents 
Intervals 
between 
treatments Application 
Assessment 
method Comment Side Effects 
(Park et 
al., 2010) 
14 Korean 
patients; 
Mean age: 
62 years 20% ALA  4h Red Halogen 100J/cm2 
100mW/
cm2 1 1 month 2 1 month 
ALA mixed 
with 
petrolatum 
was applied 
to actinic 
keratotic 
lesions 
Biopsies were 
taken for 
histological and 
IHC processing at 
the follow up 
times. 
The histological results showed a 
decrease in epidermal thickness & 
smoothing of the skin. An increase in 
total collagen & decrease in elastotic 
material was seen. When IHC was 
used, TGF-β & TGF-βIIR increased 
mainly in the epidermis & fibrillin-1 
in dermis, an increase in procollagen 
type I & III protein in the papillary 
dermis & decrease of MMP-1, 3, 12. 
The increase in TGF-β, its receptor & 
collagen type I & III mRNA support 
an increase in collagen synthesis. In 
contrast, the decrease in MMPs has 
not be seen in other studies but as 
these results are only from one time 
point. 
Variable degrees 
of erythema and 
oedema which 
was resolved in a 
few days. Some 
patients reported 
mild to moderate 
pain which did 
not need 
intervention. 
(Issa et al., 
2010) 
14 Patients 
aged 55-60 
years; 
Mean age: 
57.6 years MAL 2h 635nm LED 37J/cm2 N/A 2 
3 and 6 
months 2 4 weeks Full face 
Biopsies were 
taken for 
histology using h 
haematoxylin-
eosin (HE), 
orcein, and 
picrosirius. 
Results were 
examined by 2 
independent 
observers. 
At 6 months – 10 patients had 
improvement in skin texture, 
roughness and fine lines. Some 
patients’ elastosis was reduced 
significantly. There was an increase 
in collagen density in the papillary 
dermis.  
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Table 1.5.2 Summary of molecular studies that used PDR 
Reference 
No. of 
Patient PS & conc 
PS 
incubation 
period  
Wavelengt
h of Light 
Light 
Source 
Energy/ 
Energy 
Density 
Power/ 
Power 
Density 
No. of 
Follow 
up 
Follow up 
time  
No. of 
treat-
ments 
Intervals 
between 
treatments Application 
Assessment 
method Comment Side Effects 
(Choi et al., 
2010) 
Female 
ICR mice  16% MAL 3hr 
613–645 
nm  LED 25J 
35mW/ 
cm2 7 
day 1, 2, 4, 
8, 12, 16, 
21 1 0 
MAL was 
applied to a 
2cm area on 
the back of 
the mice. 
Western blot,  
RT-PCR, 
histology and 
zymography 
An increase in IL-1, TNF-α and TGF-
β1 mRNA was seen at day 2 after 
treatment but not in the controls. The 
increase of IL-1 & TNF-α correspond 
to the changes in MMP expression. 
An increase in MMP-2 mRNA & 
enzyme activity, MMP-3 mRNA & 
protein, & MMP-9 enzyme activity 
were observed at day 1, 2 & 4. 
Procollagen type I mRNA & protein 
began to increase after PDR treatment 
but at time points after 16 days. 
Procollagen type III mRNA & protein 
was not strongly affected but still 
showed an increase at the later time 
points. N/A 
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1.5.3. Hypericin as a novel photosensitizer 
Hypericin, an extract from St Johns Wort, was discovered in animals that grazed on it and 
developed photodermatitis, erythema and oedema illustrating photosensitization (Kiesslich 
et al., 2006). Hypericin is a second generation PS and has many attributes that make it a 
potent photosensitizing compound. Among others, it has low dark cytotoxicity, high 
quantum yield, no dark mutagenicity or carcinogenicity and a higher clearance rate from the 
body compared to other PS (Chen et al., 2001; Kiesslich et al., 2006; Kocanová et al., 2003; 
Krammer & Verwanger, 2012; O’Connor et al., 2009). Its mode of action is similar to that 
of ALA-PDR where upon light activation with specific wavelengths, according to its 
absorption coefficient, it generates reactive oxygen species with its interaction with oxygen 
(Agostinis et al., 2002; Kiesslich et al., 2006). Hypericin’s maximum absorption peaks are 
300nm-360nm (UVA) and 530-600nm (yellow light) (Figure 1.5.2). Yellow light, therefore, 
maximally activates hypericin but this PS has an added advantage in PDR as it could be 
activated by a variety of light sources. When it is irradiated, both Type I and Type II 
photochemical reactions takes place generating both singlet oxygen and superoxide anion 
amongst others (Figure 1.5.1) (Lubart et al., 2007). It is generally accepted that the Type II 
reactions generating singlet oxygen play the main role in the biological photoactivity of 
hypericin (Agostinis et al., 2011; Kiesslich et al., 2006; Kocanova et al., 2006).  
 
Figure 1.5.2 Absorption Spectrum of hypericin. 
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Hypericin is lipophilic and thus easily enters cells through the cell membrane. It has also 
been shown to bind to various serum proteins, such as human serum albumin (HSA) and 
low-density lipoprotein (LDL) in the blood. Bound to these proteins, hypericin enters the 
cells through different mechanisms and not solely through passive diffusion (Buriankova et 
al., 2011; Das et al., 1999; Gbur et al., 2009; Huntosova et al., 2010; Kascakova et al., 2005; 
Mukherjee et al., 2008; Roelants et al., 2011; Siboni et al., 2002; Uzdensky et al., 2001). Its 
subcellular localization depends on how it enters the cells and this seems to determine its 
path and final location.  
Hypericin has been shown to localise with four major cellular organelles: ER, Golgi 
apparatus, mitochondria and lysosomes. Each organelle provides a specific and vital 
function within the cell. The ER is involved in lipid and protein synthesis, protein secretion, 
metabolism of carbohydrates and detoxification of drugs (Campbell & Reece, 2002). The 
proteins are modified in the ER and leave in transport vesicles to the Golgi apparatus. The 
Golgi apparatus is involved in sorting, storing and moving these proteins to different 
locations and out of the cell (Campbell & Reece, 2002). The mitochondria are the power 
houses in cell, generating the energy in the form of adenosine triphosphate (ATP) (Campbell 
& Reece, 2002). Lysosomes are double membrane bound organelles containing lytic 
enzymes which breakdown waste materials and cellular debris. They are part of the 
endosomal pathway where an endosome will bud off from the Golgi apparatus and fuse with 
hydrolytic enzymes to create a lysosome (Campbell & Reece, 2002). 
Table 1.5.3 indicates a great disparity in the literature regarding hypericin’s end location in 
the cell i.e. ER, Golgi apparatus, mitochondria or lysosome. This table attempts to 
summarise the intracellular location of hypericin and clearly shows that hypericin appears in 
the perinuclear region in most cell types and that this location is independent of hypericin 
concentration and incubation times. However, the exact location of hypericin in specific 
organelles differed in most reports. From this data, it appears that hypericin has the ability to 
localise to all the major organelles i.e. ER, Golgi apparatus, mitochondria and lysosome. 
Moreover, culture characteristics affect its location, this includes: cell type, supplementation 
of medium, incubation time and time of visualization (Siboni et al., 2002; Theodossiou et 
al., 2009).  
Hypericin has been used in the clinical treatment of a number of dermatological conditions 
such as acne, psoriasis and actinic keratoses (Hager et al., 2009; Kascakova et al., 2008; 
Najafizadeh et al., 2012; Oztürk et al., 2007). In addition, it has been used to treat basal cell 
and squamous cell carcinomas, and other cancers of the bladder, brain and endobronchial 
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tract (Bublik et al., 2006; Chung et al., 2000; Couldwell et al., 2011; Davids et al., 2009; Du 
et al., 2007; D’Hallewin et al., 2002; Thong et al., 2006). While not used for melanoma 
treatment clinically, its efficacy in vitro has shown great promise (Davids et al., 2008,  
2009). Hypericin is a good candidate PS as it was noted that the occurrence of side effects in 
patients after treatment was low, and if it did occur, it was resolved within 24 hours 
(Kacerovská et al., 2008).  
Although hypericin’s use in PDR has not been reported before, it shows promise due to its 
success in treating other dermatological conditions. The high quantum yield indicates 
minimal energy is needed to activate hypericin to generate ROS. This bypasses the use of 
high energy and power densities that cause phototoxic reactions. 
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Author Cell Type Hypericin Location 
Hypericin 
Concentration 
Hypericin 
incubation 
time 
Organelle 
Marker Organelle 
Colocalization with 
Hypericin Special circumstances 
(Sattler et al., 1997) Caco 2 cells 
Cellular & nuclear 
membranes 0.2-0.7mM 1h         
(Vandenbogaerde et al., 
1998) A431 and HeLa cells Perinuclear 71nM 24h       
Suggest Golgi 
apparatus or ER 
localization 
(English et al., 1999) 
Neurons from El 8 Sprague-
Dawley rats 
Membranes within the 
cell 10µg/ml 30min NBD C6 ceramide Golgi apparatus Partial colocalization   
(Delaey et al., 2001) HeLa Perinuclear 1µM     
Suggest Golgi 
apparatus and ER 
localization 
(Uzdensky et al., 2001) 
Adenocarcinoma WiDr, 
Carcinoma NHIK 3025 and 
Glioblastoma D54Mg cells Perinuclear 1µM 
1h 
  
LysoTracker Blue 
DND-22 Lysosome No colocalization 
No hypericin in the 
plasma membranes 
ERTracker Blue-
White DPX ER Partial colocalization   
MitoTracker 
Green FM Mitochondria No colocalization   
(Agostinis et al., 2002) HeLa Perinuclear 0.5µM 16h 
MitoTracker 
Green FM Mitochondria No colocalization   
(Ali & Olivo, 2002) 
CNE2 & TW0-1 
nasopharyngeal carcinoma 
cells 
Cytoplasmic staining, 
perinuclear 
  
MitoTracker 
Green  Mitochondria 
Significant 
colocalization  
1.25µM 2h 
LysoTracker 
Green DND-22 Lysosome 
Significant 
colocalization  
(Siboni et al., 2002)   
murine colon carcinoma 
CT26 cells 
Perinuclear 1µM 20h LysoSensor Lysosome 
Significant 
colocalization 
Serum supplemented 
medium 
Perinuclear 1µM 1h DiOC5 ER 
Significant 
colocalization 
Serum free  
medium 
(Theodossiou et al., 2004) 
PAM 212 murine 
keratinocytes Perinuclear 5µM 3h 
LysoTracker 
Green DND-26 Lysosome 
Significant 
colocalization 
Serum supplemented 
medium 
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Author Cell Type Hypericin Location 
Hypericin 
Concentration 
Hypericin 
incubation 
time Organelle Marker Organelle 
Colocalization with 
Hypericin Special circumstances 
(Buytaert et al., 2006) HeLa, T24 cells and MEFs Perinuclear 0.5µM 16h 
ER-Tracker Blue-
White DPX ER 
Significant 
colocalization  
LysoTracker Green 
DND-26 Lysosome 
Significant 
colocalization  
Rhodamine 123 Mitochondria Little colocalization  
(Bublik et al., 2006) Squamous Cell Carcinomas Perinuclear N/A 1h         
(Pfaffel-Schubart et al., 
2006) 
U373 human glioblastoma 
cells Perinuclear 1µM 1h MitoTracker Green Mitochondria Partial colocalization 
Serum supplemented 
medium 
(Kascakova et al., 2008) U-87 MG Cells Perinuclear 30nM 5h LysoTracker Green Lysosome 
Significant 
colocalization 
Medium with/without 
serum or LDL 
supplementation 
(Davids et al., 2008) 
Keratinocytes, UCT Mel-3 
melanoma cells Perinuclear 1µM 4h MitoTracker Green Mitochondria 
Significant 
Colocalization  
Melanocytes, UCT Mel-1 
melanomas cells 
Diffuse staining in the 
cytoplasm 1µM 4h MitoTracker Green Mitochondria No Colocalization 
Suggests Golgi 
apparatus and ER 
(Galanou et al., 2008) 
DU145 cells human prostate 
carcinoma cells Perinuclear 5µM 1h 
MitoTracker™  Mitochondria 
Significant 
Colocalization 
Colocalization 
diminished at 5h 
LysoTracker™ Lysosome Partial colocalization  
ER tracker™ ER 
Significant 
Colocalization 
Slightly decreased 
colocalization at 5h 
Bodipy™ FL C5-
ceramide Golgi Apparatus 
Significant 
Colocalization Significant at 5h 
(Ritz et al., 2008) U373 MG glioblastoma Perinuclear 1µM 2h Lectin GS-II from Golgi apparatus Partial   
       ER Tracker Green ER 
Significant 
colocalization   
 (Sanovic et al., 2009) WI38 human lung fibroblasts Perinuclear 200ng/ml 16h    
Suggest Golgi 
apparatus and ER 
(Huntosova et al., 2010) U87 glioma cells Perinuclear 0.4µM 1h<    
Suggest Golgi 
apparatus and ER 
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Author Cell Type Hypericin Location 
Hypericin 
Concentration 
Hypericin 
incubation 
time Organelle Marker Organelle 
Colocalization with 
Hypericin Special circumstances 
(Vuong et al., 2011) HeLa 
Perinuclear and small 
areas in the nucleus 
2µM 30min 
   
Fixed cells with 
hypericin exposure in 
fixative 
Cytoplasm equally 
stained    
Fixed cells with 
hypericin exposure in 
serum supplemented 
medium 
Intensity decreased 
from the plasma 
membrane to nucleus    
Fixed cells with 
hypericin exposure in 
medium without serum 
Table 1.5.3 A summary of subcellular localization of hypericin within different organelles. Each studies shows different hypericin concentrations, incubation times, culture conditions and cell 
types used. (DiOC5: 3,3-dipentyloxacarbo- cyanine iodide; ER: endoplasmic reticulum)
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1.6. Project Objective 
The overall objective of this project was to develop and optimise an in vitro PDR protocol 
using the PS hypericin, activated by various wavelengths of light, on primary human dermal 
fibroblasts. 
Our laboratory and others have shown that hypericin is a good potential candidate for PDR 
as it has shown positive results in treating non-melanoma skin cancer, actinic keratosis, acne 
and psoriasis (Alecu et al., 1998; Chung et al., 1994,  2000; Najafizadeh et al., 2012). As not 
much is known about the cellular consequences of PDR on skin cells, we investigated its 
hypericin-mediated effects on primary human fibroblasts.  
Aim 1 
PDR protocols were established using various hypericin concentrations activated by three 
different wavelengths of light of varying energy and power density. 
Aim 2 
The effect of PDR on growth, migration and ROS production in primary human dermal 
fibroblasts was determined. 
Aim 3 
The subcellular location of hypericin within primary human dermal fibroblasts was 
determined, along with its association with different cellular organelles. 
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2. Chapter 2: Materials and Methods 
2.1. Tissue Culture - General maintenance 
Primary human dermal fibroblasts were donated by Dr Ingrid Baumgarten (Dept of 
Chemical Pathology, University of Cape Town) and cultured in our laboratory by Toni 
Wiggins under ethical approval REC REF: 493/2009. Cells were cultured in complete 
medium which comprised: Dulbecco's Modified Eagle Medium (DMEM) (Highveld 
Biological Pty, Ltd., Johannesburg, South Africa) and supplemented with 10%(v/v) heat 
inactivated fetal bovine serum (Highveld Biological Pty, Ltd., Johannesburg, South Africa), 
100U/ml Penicillin (Sigma, Schelldorf, Germany) and 100µg/ml of Streptomycin (Sigma, 
Schelldorf, Germany) (Appendix A for individual solutions). Cells were kept in a humidified 
incubator (Sanyo MCO-175M, Sanyo Electric Co., Osaka, Japan) with 5% Carbon Dioxide 
(CO2) atmosphere at 37°C. 
Fibroblasts were passaged by washing with phosphate buffered saline (PBS) solution before 
being incubated with 0.05% trypsin: 0.02% ethylenediaminetetraacetic acid (EDTA) 
solution for 4 minutes at 37°C. Cells passaged 10 times or less were used. Cells prepared for 
experiments were manually counted using a haemocytometer (Neubauer improved bright-
line, Marienfeld, Lauda-Konigshofen, Germany). Cells were examined regularly using a 
phase contrast microscope (Olympus Microscope Model CK2, Olympus Microscopes 
Tokyo, Japan) and photomicrographs were taken using the coupled camera system (Canon 
camera, Power shot S50, Canon Tokyo, Japan) before and after treatment to determine any 
morphological changes. 
Cells were tested regularly for the presence of mycoplasma using a Hoechst dye protocol 
(see Appendix A.1.2). All cell culture involving hypericin, cell viability and ROS assay 
reagents were performed under subdued light conditions.  
Hypericin powder (Sigma Aldrich, Schelldorf, Germany) was diluted in Dimethyl Sulfoxide 
(DMSO) to a concentration of 2mM in light subdued conditions and aliquots were stored at -
80ºC. Twenty microliter aliquots in use were kept at -20ºC.  
2.2. Uptake Assay 
The uptake assay was used to determine the time for maximum hypericin uptake into the 
cells. The hypericin concentrations were chosen from the literature as they have been shown 
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to be non-cytotoxic in other cell types (Davids et al., 2008). These concentrations were: 
0.25µM, 0.5µM, 1µM hypericin (in complete medium). 
Similar to previous protocols (Berlanda et al., 2010), cells were seeded at a density of 3x10
4
 
fibroblasts in a 35mm
 
tissue culture dish. The following day, the medium was removed and 
the 3 different hypericin concentrations were added to different dishes. Hypericin was 
incubated for 2, 4, 6, 10, 16 and 24h. At the end of the time periods, hypericin containing 
medium was removed and the cells were washed with ice-cold PBS and placed on ice. Each 
tissue culture dish had 40µl RIPA extraction buffer (Appendix A.4) added and the lysates 
collected with a rubber policeman. The lysates were centrifuged at 4°C for 20min at 
12000rpm. The supernatants were divided for the determination of protein content using the 
BCA assay (Appendix A.2) and for the quantification of hypericin on a fluorimeter. 
Hypericin fluoresces in the red light spectrum, therefore, its concentration is relative to the 
level of fluorescence detected using the fluorimeter (Cary Eclipse Fluorimeter, Varian Inc., 
Palo Alto, California, United States of America) with the following settings: 488nm 
excitation (ex) and 608nm emission (em) wavelength. Hypericin content is represented as 
arbitrary fluorescent units (AFU) per microgram of prot in and experiments were performed 
at least three times for all time points (n=3).  
2.3. Irradiation Protocol 
Three light sources were used:  
I) Eight lamps in a transilluminator emitted light in the ultraviolet range (UVA) 
(320nm to 400nm: Peak ~365nm).  
II) A DPSS solid state laser emitted continuous wavelength of light at 635nm.  
III) A DPSS solid state laser emitted continuous wavelength of light at 561nm. 
Figure 2.3.1 shows the experimental setup for the 561nm DPSS laser in our 
laboratory.  
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Figure 2.3.1 Setup for the DPSS 561nm laser 
Before irradiation with any light source, the medium was removed from the dishes and 
washed with PBS. Fresh PBS was added to the cells before irradiation to prevent 
dehydration. 
The energy density was generally determined from the literature (Table 1.5.1) with the 
power density limited due to practical constraints of the lasers. The following equation was 
used to determine the irradiation time: 
  
Equation 1.4.1 Equation used to determine, energy and power density and exposure time. 
2.4. Cell Viability Assay 
Cell viability was assessed using the XTT cell proliferation kit II (Roche, Germany). This 
colorimetric assay is based on the conversion of yellow tetrazolium salt to orange formazan 
product by mitochondrial enzymes of metabolically active cells. The change in colour is 
determined on an ELISA plate reader (VERSAmax™ tuneable microplate reader, Molecular 
Devices, Sunnyvale, CA, USA; Software: Softmax Pro version 4.3.1) with an absorbance of 
450nm. 
Cells were seeded at a density of 3x10
4
 cells per well in 200µl of complete medium in a 96-
well plate and left to adhere overnight. The following day the medium was replaced with the 
three hypericin concentrations (0.25µM, 0.5µM and 1µM) in complete medium, along with 
a vehicle (DMSO) containing complete medium or fresh medium for an untreated control, 
for 16h. After this time, the wells were washed with PBS then irradiated in 100µl PBS with 
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the various light sources using several energy and power densities to determine a non-
cytotoxic irradiation protocol. Table 2.4.1 presents the various irradiation times and energy 
and power densities. One plate was used when irradiating with the 635nm DPSS laser and 
the UV transilluminator lamps. One side was irradiated and the opposite side was covered 
with foil and served as the sham or unirradiated control. It is important to note that when the 
561nm DPSS laser was used, the unirradiated cells were seeded on a separate plate because, 
at high energy doses and power densities, the unirradiated control was affected by scattered 
light through the transparent plate. The unirradiated or sham controls would determine if 
hypericin on its own has any effect on primary human dermal fibroblasts. 
  
Diameter 
(cm) 
Area 
(cm
2
) 
Dose 
(J/cm
2
) 
Power 
(mW) 
Power 
Density 
(W/cm
2
) 
Time of 
Exposure 
(sec) Assay 
Yellow 0.5 0.20 0.1 2 0.0102 9.821 Cell Viability 
Yellow 0.5 0.20 0.25 2.00 0.0102 24.554 Cell Viability 
Yellow 0.5 0.20 0.50 2.00 0.0102 49.107 Cell Viability 
Yellow/Red 0.5 0.20 1.00 10.00 0.0509 19.643 Cell Viability 
Yellow/Red 0.5 0.20 2.50 10.00 0.0509 49.107 Cell Viability 
Yellow/Red 0.5 0.20 5.00 10.00 0.0509 98.214 Cell Viability 
Yellow 0.5 0.20 1.00 20.00 0.1018 9.821 Cell Viability/ROS 
Yellow 0.5 0.20 2.50 20.00 0.1018 24.554 Cell Viability 
Yellow 0.5 0.20 5.00 20.00 0.1018 49.107 Cell Viability 
UVA 0.5 0.20 0.50       Cell Viability 
UVA 0.5 0.20 1.00       Cell Viability/ROS 
Yellow 1.5 1.77 1.00 179.00 0.1013 9.876 
Growth 
Curve/ROS/Scratch 
UVA 3.5 9.63 0.50       Growth Curve 
Red 3.5 9.63 2.50 24.00 0.0025 1002.604 Growth Curve 
Yellow 3.5 9.63 5.00 20 0.0020 240.625 Growth Curve 
Table 2.4.1 Variables used in the different irradiation protocols for each wavelength of light. 
Yellow is light from the 561nm DPSS laser, Red is light from the 635nm laser and UVA is light 
from the transilluminator lamps. Diameters: 0.5cm = 96-well plate, 1.5cm = 24-well plate, 3.5cm 
= 6-well plates/35mm tissue culture dish. 
Following irradiation, PBS was removed and 200µl of complete medium was added for a 
24h recovery period. Four hours before the end of this recovery period the XTT solution 
(Roche, Germany) was prepared according to the manufacturer’s instructions (Appendix 
A.6) and 50µl of the combined solution was added to all the wells in subdued light 
conditions. Twenty four hours after the irradiation, plates were analysed on an ELISA plate 
reader where the absorbance of XTT was determined at 450nm. The percentage of viable 
cells was established by normalization to the combined values of unirradiated, untreated and 
vehicle treated controls. Figure 2.4.1 is a schematic of the timeline for the cell viability 
assay. 
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Figure 2.4.1 A timeline showing the protocol for the cell viability assay (96 = 96 well plate) 
2.5. Growth Curve  
Cells analysed to establish growth curves were seeded in either 35mm
 
diameter dishes, 6-
well plates or 24-well plates both at a density of 1x10
4
 cells per dish or well and allowed to 
adhere overnight. The following day hypericin in medium was added to those dishes to be 
treated with PDR. Table 2.5.1 summarises the hypericin concentrations used with each light 
source.  
 
Hypericin Concentration 
(µM) 
Energy dose 
(J/cm
2
) 
Power Density 
(W/cm
2
) 
UVA lamps 0.25 0.5   
635nm DPSS Laser 0.5 2.5 0.0025 
561nm DPSS Laser 0.25 1 0.102 
Table 2.5.1 Summary of hypericin concentrations, energy doses and power densities 
After 16h hypericin incubation, the cells were washed with PBS and 1ml or 0.5ml of PBS 
was added to the 35mm dish or 24-well plate well, respectively. The dishes were irradiated 
with the energy dose and power density indicated in Table 2.5.1 
When the 561nm DPSS laser was used, the growth rate of cells treated with the laser beam 
and the vehicle (0.0125v/v% DMSO) alone was also determined. This was performed to see 
the effect of the laser alone on the cells.  
Cells were counted using a haemocytometer (Neubauer improved bright-line, Marienfeld, 
Lauda-Konigshofen, Germany) 24h post-irradiation and every alternate day thereafter for 7 
days. Medium was changed every 3 days in all the dishes or wells. Except with the 561nm 
DPSS laser where the medium was only changed once on day 3. Of note, the red and UVA 
light growth curves had 3 intra-experiments repeats but only one inter-experiment repeat due 
to limited access to these light sources. 
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2.6. Reactive Oxygen Species (ROS) Assay 
2.6.1. FACS Method  
Reactive oxygen species (ROS) were quantified using initially the non-fluorescent dye, 5(6)-
Carboxy-2′,7′-dichlorofluorescein diacetate (DCF-DA) (Sigma-Aldrich, Schnelldorf, 
Germany), whereupon interaction with ROS, is converted to an oxidized state and fluoresces 
green. The fluorescence can be detected on a fluorescent activated cell sorter (FACS) using 
the 488nm argon laser. 
One hundred thousand cells (1x10
5
) were seeded into 35mm dishes. After 24h, the medium 
was replaced with the relevant hypericin concentration in complete medium for each light 
source. Cells to be treated with the UV transilluminator and yellow laser (561nm DPSS) 
were both incubated with 0.25µM hypericin for 16h. Following irradiation (Table 2.5.1), the 
medium was replaced with fresh medium that contained 40µM DCF-DA (Appendix A.7) for 
30 minutes at 37°C in the incubator. It is important to note, for this method the power was at 
20mW. This meant the power density was 0.002W/cm
2
. Following this, the cells were 
washed with PBS and collected by trypsinization. The cells were pelleted at 2500rpm at 
room temperature and rinsed in 1ml PBS and re-pelleted. Cells were re-suspended in in 
500µl PBS, transferred to FACS tubes (BD Falcon tubes, BD Biosciences, Becton 
Dickinson International, Erembodegem, Belgium) and analysed on the FACS machine 
(FACS Calibur, Division of Immunology, UCT). 
DCF-DA was detected in the FLH-1 channel with hypericin being detected in the FLH-3 
channel and 10 000 events/cells were analysed. All data generated were analysed using 
CellQuestPro software (version 5.2.1, BD Biosciences, California, United States of 
America). Results are presented as a percentage of the control, which indicated basal levels 
of ROS. All samples were gated to only analyse live cell events in the population. 
2.6.2. Fluorimeter Method 
For a comparison between FACS analyses of ROS, a fluorimeter-based assay was 
developed. Ninety-six well white tissue culture plates (Greiner Bio-One, Frickenhausen, 
Germany) were seeded with 3x10
4
 cells per well, the same number used in the cell viability 
assay with the design setup in Figure 2.6.1. Cells were treated with either 0.25µM hypericin 
or 0.0125% DMSO for 16h and irradiated with the yellow laser (1J/cm
2
, 100mW/cm
2
) or 
UVA (1J/cm
2
). Following this, cells were incubated with 10µM DCF-DA for 30 minutes in 
the incubator at 37°C. After this, the cells were washed and 100µl PBS was added to each 
well. The plate was analysed on a fluorimeter at an excitation of 488nm and emission of 
535nm. The blank for the experiment were the untreated cells, which had not been exposed 
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to DCF-DA. The results were normalized to the DCF-DA only treated cells. The following 
experimental setup was used: 
 
Figure 2.6.1 Experimental design for the two 96-well plates for the fluorimeter based assay 
where DCF-DA's fluorescence to determine ROS generated. Irradiated plate was either exposed 
to yellow laser light (1J/cm
2
, 100mW/cm
2
) or UVA (1J/cm
2
) whereas the u irradiated plate was 
kept in the dark. 
2.7. Scratch Assay 
Figure 2.7.1 shows the experimental setup for the scratch assay. Two plates were used with 
one kept in the dark and the other irradiated with laser light. One hundred thousand cells 
were seeded in a 24-well tissue plate and allowed to adhere overnight. The following day the 
medium was replaced with 10ug/ml of mitomycin C in complete medium for 2-3h to halt 
proliferation of the dividing cells. The cells were thoroughly washed with PBS four times 
before complete medium was added. A scratch was made across the well with a pipette tip. 
Photographs of the scratch were taken immediately using a Zeiss Axiovert 200M fluorescent 
microscope (Carl Zeiss Microscopy GmbH, Germany).  
 
Figure 2.7.1 The experimental design for the two 24-well plates used in the scratch assay. One 
plate was irradiated with 1J/cm
2
, 100mW/cm
2
 yellow laser light and the other was kept in the 
dark.   
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Cells were exposed to either 0.25µM hypericin or 0.0125% (v/v) DMSO for 16h and 
thereafter irradiated with the same parameters as the yellow laser growth curve (1J/cm
2
, 
100mW/cm
2
). Eight hours after irradiation with the laser, a total of 24h after making the 
scratch, photographs were taken to determine the decrease in the area of the scratch. The 
photographs were aligned in GIMP (GNU Image Manipulation Program, version 2.6.11) and 
the area was determined using the software programme Axiovision (Carl Zeiss 
MicroImaging GmbH, Germany, Version 4.8.2.0). The results are shown as a percentage of 
wound closure after 24h. Figure 2.7.2 is the timeline for this experiment.  
 
Figure 2.7.2 Timeline for the scratch assay (24 = 24 well-plate; Hyp = hypericin) 
2.8. Subcellular Localization using Transfection  
To determine the subcellular localization of hypericin, we used plasmids targeted to specific 
organelles expressing fluorescent proteins and used scanning confocal microscopy to 
visualize the fluorescence (Zeiss Axiovert 200M LSM 510 META Confocal microscope, 
Carl Zeiss Microscopy GmbH, Germany). The table below describes the targeted organelles, 
parent plasmid, gene used to specify each organelle and the colour of the fluorescent protein 
tag (Table 2.8.1). Plasmid maps and references are in the Appendix A.9. 
Organelle Plasmid 
Targeting 
sequence/Gene Fluorescent Protein 
ER  pEYFP  Calreticulin Yellow  
Golgi 
apparatus  pEGFP-C1 Rab7WT Green 
Mitochondria  pEGFP-N1 OTC Green 
Table 2.8.1 Plasmids used in the subcellular localization experiments indicating: organelle 
targeted, parent plasmid, gene inserted in plasmid and the colour of the fluorescent protein. 
Transfections were performed by seeding cells (1x10
5
 cells) to obtain approximately 70% 
confluency on 22mm
2
 glass coverslips placed inside 35mm
 
diameter tissue culture dishes. 
The Jet Pei transfection reagent (PolyPlus Transfections, New York, USA) was used for the 
transfections and the protocol followed the manufacturer’s instructions. Briefly, for each 
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sample, 0.5µg plasmid DNA was added to 50µl of 150mM NaCl. The mixture was vortexed 
and centrifuged. In a separate centrifuge tube, 2µl of Jet Pei transfection reagent was added 
to 50µl of 150mM NaCl, vortexed and centrifuged. The solution containing the plasmid was 
added to the transfection reagent solution and gently triturated. The combined solution was 
left at room temperature for 15-20 minutes and then added to the dishes, without changing 
the complete medium, in a drop-wise manner. 
The dishes were left in the incubator at 37°C for 24h after which 0.25µM hypericin in 
complete medium was replaced in specified dishes while the control dishes were left. All the 
dishes were left for a further 16h. At the termination of the experiment all the dishes were 
stained with 5µg/ml Hoechst in medium for 30 minutes at 37°C (Appendix A1.1). The 
Hoechst was removed and replaced with fresh medium until viewing.  
Immediately before viewing the dishes were taken out of the incubator and the coverslips 
were mounted onto glass slides in medium without fetal calf serum and viewed live on the 
confocal microscope. The blue argon 488nm laser on the confocal microscope visualized the 
GFP and YFP localised in the organelles. The laser used to visualise the hypericin in the cell 
was the same type of laser used during the other experiments (DPSS 561nm laser). We, 
therefore, have the ability to activate the cells in a similar way and see their reaction 
immediately after irradiation. However, the energy and power density will not be same as 
the cell viability assay as the power needed to detect hypericin’s fluorescence is higher as for 
visualisation on the microscope. The two-photon infra-red laser was used to detect the 
Hoechst localized in the nucleus. The order of detecting each label using the individual 
lasers was kept the same so we could visualize the organelles before hypericin activation 
(GFP/YFP<hypericin<nucleus). To determine colocalization in the cells, profiles and 
scatterplots were used to interpret the images using the LSM and Zen software (2009, Carl 
Zeiss Microscopy GmbH, Germany) 
2.9. Statistical Analyses 
The statistical program Graphpad Prism (Version 5, Graphpad Software Inc., California, 
United States of America) was used for all analysis. Differences in values were stated as 
significant if the p-value was less than 0.05.  
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3. Chapter 3: Results 
3.1. Cellular Uptake of Hypericin 
To determine hypericin’s maximum cellular uptake, primary human fibroblasts were 
incubated with three different hypericin concentrations (0.25µM, 0.5µM, 1µM) over a time 
course (2.5h-24h). After each time period, cell lysates were collected for analysis. The total 
cellular protein concentration was quantified using a BCA assay (Section A.2) and the 
fluorescence of hypericin was determined on a fluorimeter with the settings 488nm for 
excitation and 608nm for emission. Hypericin is an autofluorescent compound, thus the 
amount of fluorescence is related to its concentration within a cell (Kascakova et al., 2008; 
Sattler et al., 1997; Theodossiou et al., 2004). The results are presented as Arbitrary 
Fluorescent Units per microgram of protein (AFU/µg of protein).  
The three hypericin concentrations (0.25µM, 0.5µM, 1µM) were shown to be non-toxic in 
other cell types. Over the time course of the experiment (2.5-24h), cellular uptake displayed 
a time-dependent increase in fluorescence with all three concentrations peaking between 10-
16h (Figure 3.1.1).  
 
Figure 3.1.1 The cellular uptake of hypericin over 2.5-24h for three hypericin concentrations (0.25µM, 
0.5µM and 1µM) in primary human dermal fibroblasts. Results measured in AFU per µg of protein and 
represented as mean±SEM (n=3). Solid black lines signifies p<0.05 for 0.5µM time points and the solid red 
line signifies p<0.05 for 1µM times points. Significance calculated using ANOVA with the Bonferroni post-
test. 
The lowest hypericin concentration (0.25µM) showed a gradual increasing trend with peak 
fluorescence at 16h (Figure 3.1.1). There was no significant difference between any of the 
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time points (p>0.05). The 0.5µM hypericin concentration peaked at 10h and showed a 
significant increase from the two earlier time points (2.5h and 4h) with no significant 
difference displayed between 10h and later time points (16h and 24h). In contrast, the 
highest hypericin concentration (1µM) used, showed a significant increase between 4 and 
10h. Similarly to the 0.5µM hypericin concentration, the 1µM hypericin showed the greatest 
AFU/µg of protein at 10h with no difference between this peak and later time points. In 
comparing the three concentrations’ value to one another, the 1µM concentration had a 
highest AFU/µg of protein values with 0.5µM being second and 0.25µM having the lowest 
values at all time points (Figure 3.1.1). These results were semi-quantitatively confirmed 
using fluorescent microscopy (see images Figure A.8.1) 
In experiments that followed, 16h exposure was chosen as it had the highest AFU/µg of 
protein values for 0.25µM hypericin. In addition, there was no significant difference 
between 10h and 16 h for both 0.5µM and 1µM hypericin. This incubation time is in line 
with the literature where 16h has the greatest uptake of hypericin in other cell types such as 
A431 human epidermoid carcinoma, T24, HeLa cells and mouse embryonic fibroblasts 
(Berlanda et al., 2010; Hendrickx et al., 2005). 
3.2. Cell Viability of Fibroblasts after PDR Treatment 
PDR involves the uptake of the PS and subsequent irradiation of the cells with an activating 
wavelength of light. The variables in the irradiation protocol, such as energy, power density 
and irradiation time, are important to consider for the best possible outcome for this therapy. 
To test this, a cell viability assay was performed using three light sources to determine an 
irradiation protocol that was non-cytotoxic with 3 hypericin concentrations. The assay used 
tetrazolium salt which is indicative of mitochondrial metabolic function and correlates to 
cell viability. As this therapy will be used for clinical applications in skin rejuvenation, 
cytotoxic reactions are not desirable and must be avoided.  
Two different types of light sources, lamps and lasers, were used to activate the three 
hypericin concentrations (0.25µM, 0.5µM and 1µM) used in the uptake assay. A bank of 
eight lamps in a transilluminator delivered light in the UVA range (320nm-400nm) with a 
peak output of 365nm. Two solid state DPSS lasers emitted continuous-wave, coherent light 
at 632nm (red) and 561nm (yellow). The 561nm laser (now referred to as the yellow laser) 
and UVA lamps were chosen as these wavelength were shown to be maximally absorbed by 
hypericin according to its absorbance spectrum (See Figure 1.5.2). Light from the 632nm 
laser (now referred to as the red laser) is approximately one third as effectively absorbed by 
hypericin but this wavelength is often used in dermatology to treat skin conditions and is 
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therefore readily available in dermatological clinics (Dierickx & Anderson, 2005; Peplow, 
Chung, & Baxter, 2012a) 
Energy and power density refer to energy delivered and its rate within a certain area, 
respectively. The energy density is most often reported in the literature as a defining variable 
for the irradiation protocol in previous PDR studies (Table 1.5.1). Reports ranging from 
photorejuvenation, PDT and PDR trials were used to determine a range of energy densities 
that would not be detrimental to cell survival or demonstrate skin phototoxicity. Low level 
energy and power densities were chosen as they have been shown to be stimulatory to 
fibroblasts (Lubart et al., 2005). Our overall aim was to determine a protocol where minimal 
energy was used to activate hypericin to prevent phototoxic reactions occurring during PDR. 
However, the energy must still be at a level where ROS is produced to be stimulatory. 
3.2.1. Red (635nm) Laser 
Red light is able to penetrate deep into the dermis due to its long wavelength (Agostinis et 
al., 2011; Peng et al., 2008). Although red light does not activate hypericin to the same 
extent as UVA and yellow light, it may be beneficial due to its penetration into the skin.  
Cells were exposed to the three hypericin concentrations (0.25µM, 0.5µM and 1µM) for 16h 
and irradiated with three different energy densities at one power density. The lowest energy 
density, 1J/cm
2
, displayed no difference in cell viability compared to the control (Figure 
3.2.1). In contrast, 2.5J/cm
2
 displayed a significant increase in cell viability of cells exposed 
to 0.25µM (111.7±9.95%) and 0.5µM (117.5±8.49%) hypericin. Interestingly, 5J/cm
2 
showed no significant change at any of the hypericin concentrations (See Figure 3.2.1). 
Based on these results, 2.5J/cm
2
 red laser light seemed to be the threshold amount for cell 
stimulation using the red laser while higher energy density led to no change in cell viability.  
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Figure 3.2.1 The percentage of viable cells 24h after PDR treatment with 3 hypericin concentrations 
activated by red laser light using 3 different energy densities. Results were normalised to a 100% against 
the dark control and represented as mean±SEM (n=3). * represent p values <0.05 for 0.5µM hypericin 
using the student’s t-test to the unirradiated control. 
3.2.2. UV transilluminator 
UVA light was investigated not only because of its high absorbance coefficient with 
hypericin but through its ability to penetrate the dermis (Figure 1.5.2) (Peng et al., 2008). A 
drawback of UVA is its propensity to generate high ROS levels. This led us to use a dose of 
1J/cm
2
 or less as higher energy densities may generate adverse side effects. Twenty four 
hours after hypericin activation with 0.5J/cm
2
 UVA light, results showed a significant 
decrease in cell viability at 1µM hypericin (Figure 3.2.2). Interestingly, there was a slight 
increase (112.4±25.12%) in cell viability at the lower hypericin concentration (0.25µM) 
when irradiated with 1J/cm
2
 (Figure 3.2.2). Conversely, there was a drastic decrease in cell 
viability when 1µM was irradiated with 1J/cm
2
 (Figure 3.2.2). Interestingly, previous work 
done in our group showed that 1µM hypericin with 1J/cm
2
 was not cytotoxic in melanoma 
cells. This indicates that fibroblasts are more sensitive to UVA activated hypericin compared 
to melanoma cells which indicate a possible cell type dependency with this therapy. 
* 
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Figure 3.2.2 The percentage of viable cells 24h after PDR treatment with 3 hypericin concentrations 
activate by UVA light using 2 different energy densities. Results were normalised to a 100% against the 
control and represented as mean±SEM (n=3). * represent p-values <0.05 for 1µM hypericin using the 
student’s t-test to the unirradiated control. 
One limitation in using the UVA transilluminator was that only energy density was 
available. This meant the power or power density could not be fully investigate, thus, 
limiting the use of UVA as an activating light source in our PDR protocol. A laser can 
overcome this as power is used to determine the energy density through the time of exposure 
(Equation 1.4.1). We, thus, investigated the effect of varying, not only the energy density, 
but also the power density using the yellow laser.  
3.2.3. Yellow (561nm) Laser 
Due to the optimal spectral characteristics of hypericin where 563nm light is maximally 
absorbed, yellow light (561nm) was used. In contrast to UVA and red light, most of this 
wavelength of light is captured by hypericin. This implies that less energy could be used to 
result in the same downstream effects, i.e. ROS generation, compared to other wavelengths. 
It follows that less energy, power and exposure time would most likely negate side-effects 
caused by overexposure to light, such as erythema and oedema. 
Following the data gathered from the red laser and UV transilluminator, a range of energy 
density from 0.1 J/cm
2
 to 5J/cm
2
, with associated power densities, were tested. The results 
show a clear increase in cell viability at the lower energy densities (Figure 3.2.3). As the 
energy and power increased, there was both a hypericin- and energy dependent decrease in 
cell viability (Figure 3.2.3). Similarly, to the red light, there is a threshold point where the 
PDR treatment changed from being beneficial and having a positive effect on the cell to one 
where it was cytotoxic. This tipping point occurs at the higher hypericin concentration 
(0.5µM and 1µM) and energy densities above 2.5J/cm
2
. 
* 
* 
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Figure 3.2.3 The percentage of viable cells 24h after PDR treatment with 3 hypericin concentrations 
activated by yellow laser light using several different energy and power densities. Results were normalised 
to a 100% against the control and represented as mean±SEM (n=3). * represents p-value<0.05 for 0.25µM 
hypericin, # represents p-value<0.05 for 0.5µM hypericin, § represents p-value <0.05 for 1µM hypericin 
using the student’s t-test to the unirradiated control. 
It appears the low energy density within each power density showed an increase in viability 
whereas the higher energy results in a decrease. The most drastic reduction was observed 
with 5J/cm
2
 (50mW/cm
2
) of light and 1µM hypericin (45.36±12.4%), resulting in a major 
loss of viable cells. In contrast, the 100mW/cm
2
 power density, with its associated energy 
densities, did not result in as drastic a decrease compared to those using 50mW/cm
2
. This 
could be explained by the length of time of irradiation being twice as long for 50mW/cm
2
 
compared to the 100mW/cm
2
 for the same energy density. This arises from the inverse 
relationship between power and time (Equation 1.4.1) therefore by doubling the power from 
50 to 100mW/cm
2
, the time would be halved for the same energy. The extended time might 
have negative effects of excessive heating or prolonged activation of hypericin thereby 
generating overwhelming amounts of ROS. 
The increase in cell viability was seen constantly with 0.25µM hypericin and low energy 
densities. Interestingly, both 10 and 100mW/cm
2
 had an increase of 20% in cell viability 
(Figure 3.2.3). Noteworthy, is that an increase in this assay could indicate an increased cell 
number or mitochondrial function as compared to the control. The therapy could, therefore, 
causes an increase in proliferation or activation of cell metabolism through mitochondrial 
stimulation. To investigate the increase seen in cell viability and its relation to the 
proliferation rate, growth curves were performed for each light source. 
* * 
§ 
§ 
§ 
# 
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3.3. Effect of PDR on the Growth of Fibroblasts 
The growth curves were conducted over seven days to determine PDR’s effect on cell 
proliferation. Similarly to the cell viability assay, the effect of hypericin activation with 3 
different wavelengths of light on growth was assessed.  
3.3.1. Red (635nm) Laser 
Fibroblasts were seeded into 6-well plates and were either treated with 0.5µM hypericin for 
16h or left untreated. The hypericin treated cells were washed and irradiated with 2.5J/cm
2
 
(2.5mW/cm
2
) of red laser light. Three wells are counted on the first day after hypericin 
activation and every alternate day over the 7 day period. The results of each day were 
standardised to the average cell count 24h post-irradiation and represented as a fold increase. 
The proliferation rates of both untreated (no hypericin or light) and PDR treated cells 
showed an exponential increase 3 days after PDR treatment (Table 3.3.1 and Figure 3.3.1). 
Red light from any light source has been shown to stimulate fibroblasts which may explain 
the slight increase in proliferation of the treated cells compared to the control cells (Figure 
3.3.1) (Peplow, Chung, & Baxter, 2012a).  
 
Table 3.3.1 Fold increase of cell number: after PDR treatment using 2.5J/cm2 (2.5mW/cm2) red light to 
activate 0.5µM hypericin and control cells. SD – standard deviation. 
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Figure 3.3.1 A growth curve of primary human fibroblasts over 7 days. Solid red line represents 
cell after PDR treatment using 0.5µM hypericin and 2.5J/cm
2
 (2.5mW/cm
2
) red laser light. The 
solid black line represents control cells. The results are presented as mean ±SEM (n=1) 
3.3.2. UV transilluminator 
The experiments using the UVA transilluminator as the activating light source followed the 
same rationale as the red laser (Section 2.5). All hypericin treated dishes were placed in the 
transilluminator and simultaneously irradiated with 0.5J/cm
2
. Results showed no significant 
difference between the PDR treated and untreated control cells. The treated cells showed a 
slightly slower proliferation rate (Table 3.3.2) compared to the untreated cells over a period 
of 7 days (Figure 3.3.2). UVA light on its own may cause a lower proliferation rate. This is 
due to this wavelength’s ability to generate ROS. The combined effect of UVA and PDR in 
generating ROS appears, therefore, may cause a transient retardation in the proliferation rate 
of fibroblasts. 
 
Table 3.3.2 Fold increase of cell number: after PDR treatment using 0.5J/cm2 UVA light to activate 
0.25µM hypericin and control cells. SD – standard deviation. 
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Figure 3.3.2 A growth curve of primary human fibroblasts over 7 days. Solid line represents cell after PDR 
treatment with 0.25µM hypericin and 0.5J/cm2 UVA. The solid black line represents control cells. The 
results are presented as fold increase after day 1. Data represented as mean±SEM. (n=1) 
3.3.3. Yellow (561nm) Laser 
To determine the effect of yellow laser-activated hypericin on the growth rate of fibroblast, 
cells were firstly seeded into 24-well plates. The smaller diameter meant that the same 
power density as the cell viability assays was used.  This required increasing the power 
output of the laser itself (see Table 2.4.1). Interestingly, there was no significant difference 
between the irradiated cells only and the PDR-treated cells (Figure 3.3.3). However, similar 
to the PDR treated cell using UVA, a slight decrease in the proliferation rate of the irradiated 
and PDR treated cells compared to the control cells (Figure 3.3.3).  
 
Table 3.3.3 Fold increase of cell number after: PDR treatment where yellow laser light (1J/cm², 
100mW/cm²) activated 0.25µM hypericin, yellow laser light irradiated cells only and the control cells. SD – 
standard deviation. 
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Figure 3.3.3 A growth curve of primary human fibroblasts over 7 days. Solid red line represents cell after 
PDR treatment with 0.25µM hypericin and 1J/cm2 (100mW/cm2) yellow laser light. Fine green dashed line 
represent cells irradiated with 1J/cm2 (100mW/cm2) yellow light only. The coarse black dashed line 
represents control cells. The results are presented as fold increase after day 1. Data represented as 
mean±SEM (n=3). 
In summary, these data show irradiating hypericin-treated fibroblasts with different 
wavelengths of light have different effects on growth. The red laser activation of hypericin 
was tending toward an increase in proliferation rate and UVA and yellow wavelengths 
showed a slight decrease in growth. All three wavelengths had no significant effect on 
proliferation on hypericin-treated fibroblasts as growth returned to normal after several days 
i.e. the cells did not become cytostatic. As previously mentioned, the increase in the cell 
viability assay seen with each wavelength (Section 3.2) either reflects increased growth or 
activity in the cell. We can conclude from these growth curves, that the increase in cell 
viability was not related to the proliferation rate. 
3.4. Effect of PDR on Migration of Fibroblasts 
The response in fibroblast activity is similar in wound healing and rejuvenation regarding 
cytokine and growth factor alterations (Fisher et al., 2008; Grotendorst et al., 2004; Varga et 
al., 1987). The scratch assay was performed as it simulates a wound situation. This allows 
for a 2 dimensional analysis of the impact of various treatments on the cell. The fibroblasts 
were treated with 10µg/µl mitomycin C which stops proliferation by inhibiting DNA 
synthesis and allows for the assessment of migration alone. In the experiments cells were 
grown to a confluent monolayer in a well. A “wound”/scratch was then made in the tissue 
culture plate well. Photographs of the entire wound were taken at this and one other time 
point (before and 8h after irradiation) to monitor the rate of fibroblast migration and results 
were presented as a percentage of wound closure over 24h. 
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After 16h incubation with hypericin, the irradiation plate was exposed to 1J/cm
2
 
(100mW/cm
2
) of yellow laser light. Eight hours post-irradiation, and 24h after the initial 
scratch was made, the wells were photographed. The photographs were processed and the 
area of the entire wound was determined before and after the PDR treatment.  
 
 
Figure 3.4.1 Cell were treated with 0.25µM hypericin for 16h and irradiated with 1J/cm2 (100mW/cm2) 
yellow laser light. The wound closure was determined 24h after the scratch was made and 8h after yellow 
laser irradiated. (A) Representative images of a cross sectional of a “wound”/scratch made in a confluent 
fibroblast monolayer with the red lines marking the borders of the wound. These borders were used to 
calculate the area using AxioVision software. (B) The results are represented as the percentage of wound 
closure between 0-24h and shown as mean±SEM (n=3). 
Twenty four hours after making the scratch, the untreated and unirradiated cells had 
54±2.427% wound closure. The unirradiated (47.47±22.06%) and irradiated vehicle 
(46.37±10.14%) controls and unirradiated hypericin (44.07±29.01%) controls had a similar 
amount of closure as the untreated, unirradiated cells (Figure 3.4.1 (B)). Surprisingly, the 
irradiated cells exposed to hypericin displayed a significantly slower closure rate 
(24.42±15.06%), compared to the controls (Figure 3.4.1 (B)). This raises the possibility that 
(A) 
(B) 
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yellow laser-activated hypericin seems to significantly affect wound closure through the 
decreased rate of fibroblast migration. This lack of movement by the cell indicates that 
alternative cellular energy processes may be activated through PDR (See Section 4). 
3.5. Determination of Reactive Oxygen Species (ROS) 
after PDR treatment 
ROS is the product of PDR and a potential mediator of this therapy. The effectiveness of 
PDR can, therefore, be monitored by quantifying the amount of ROS generated. A ROS 
assay was performed to confirm the hypericin concentration and irradiation protocols were 
indeed generating ROS. We performed a ROS assay using the dye DCF-DA. When this 
compound is oxidised by ROS it fluoresces green. It can detect various ROS and reactive 
nitrogen species (RNS) (Halliwell & Gutteridge, 2007b). The fluorescence can be visualised 
through various methods. This study used two methods to determine fluorescence - flow 
cytometry, where cell were passed through a fluorescent activated cell sorting (FACS) 
machine, and a fluorimeter, to determine fluorescence levels in a white tissue culture plate. 
3.5.1. ROS assay: FACS method 
Cells were seeded into 35mm tissue culture dishes and underwent PDR therapy. Following 
irradiation, cells were incubated with 40µM DCF-DA in complete medium for 30min at 
37°C. Cells were collected, washed and resuspended in FACS tubes.   
Both yellow laser and UVA light were used to measure their activation of 0.25µM hypericin. 
UVA (1J/cm
2
) treated cells served as the upper limit of ROS generation. Yellow laser light 
treated cells were irradiated with 1J/cm
2 
and 20mW. The power was not adjusted for the 
change in area from a 96-well plate (cell viability assay) to a 35mm tissue culture dish as 
this would require an extraordinary higher power output beyond that of the laser used. 
Instead the power density was calculated to be 0.002W/cm
2
, which translated to the cells 
receiving 8min of irradiation (Table 2.4.1).  
The results were normalized to 100% of the untreated, unirradiated control which 
represented basal levels as seen in Figure 3.5.1. Cells irradiated with the yellow laser light 
alone showed an increase of 72±83.52% in ROS generation. Whereas yellow laser 
irradiated-hypericin treated fibroblasts showed a 96±23.55% increase in ROS levels higher 
than the control (Figure 3.5.1). Incubation with hypericin and yellow laser light irradiation 
showed ROS generation was 24% higher than light alone. UVA irradiated cells exposed to 
hypericin had the highest ROS generated with 186±22.66% compared to the control.  
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Figure 3.5.1 Results of ROS assay using flow cytometry based method. Basal represents basal ROS levels 
where only DCF-DA was added to the cells. Yellow only are cells irradiated with 1J/cm2 (100mW/cm2) 
yellow laser light only, 0.25µM was added to two samples where one as irradiated with 1J/cm2 
(100mW/cm2) yellow laser light and the other 1J/cm2 UVA. Data represented as mean±SEM (n=3). 
 
3.5.2. ROS assay: Fluorimeter method 
An additional method of ROS detection was employed to clarify results presented in Section 
3.5.1. A 96-well based assay was developed which used a fluorimeter to detect the green 
fluorescence of oxidised DCF-DA. Cells were seeded onto white tissue culture grade 96-
well plates at a density of 3x10
4
 cells per well. White plates, as opposed to clear tissue 
culture plates, were used as they allow for sensitive fluorescence readings using a 
fluorimeter, as well as stopping light from scattering during irradiation.  
The hypericin concentration was 0.25µM and the irradiation protocol used was yellow laser 
light delivered at 1J/cm
2
 (100mW/cm
2
) and for the UVA treated plate it was 1J/cm
2
 (the 
same irradiation used during the cell viability assay). After irradiation, 10µM DCF-DA in 
complete medium was added to each well and incubated for 30min at 37°C. Each well had 
100µl PBS added to it before the fluorimetric reading. The cells were not removed from the 
wells and the fluorimeter was set at 488nm for excitation and 535nm for emission to analyse 
the total fluorescence present in each well. 
The cells treated with yellow laser light alone showed no difference to the control 
(5±75.65% increase) (Figure 3.5.2). In contrast, cells incubated with hypericin and irradiated 
with yellow laser light showed a 42±75.54% increase in ROS levels (Figure 3.5.2). 
However, the variance in the sample was large which made standard statistical test 
inappropriate thus the Welch’s test was used to account for this. It was found that yellow 
laser-activated hypericin was not significantly different to the control (p-value = 0.057). 
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Interestingly, hypericin and UVA light resulted in a significant increase (56±53.82%) in 
ROS levels in the fibroblasts (Figure 3.5.2) (p-value 0.0116).  
 
Figure 3.5.2 ROS levels using fluorimeter based method. Basal represents basal ROS levels where only 
DCF-DA was added to the cells. Yellow only are cells irradiated with 1J/cm2 (100mW/cm2) only, 0.25µM 
was added to two samples where one was irradiated with 1J/cm2 (100mW/cm2) yellow laser light and the 
other 1J/cm2 UVA. Data represented as mean±SEM (n=3). 
Overall, both methods showed that activating hypericin with either yellow laser or UVA 
light, led to an increase in ROS. Moreover, UVA light consistently generated more ROS 
than yellow laser light in activating hypericin. This indicates that ROS generated through 
hypericin activated by yellow laser light will, most likely, not have negative effects on 
human dermal cells and may in fact have downstream effects on cellular metabolism 
regarding the dermal matrix. 
3.6. Hypericin colocalization with organelle specific 
labels 
Colocalization of hypericin has been shown to influence the cellular response (Buytaert et 
al., 2006; Theodossiou et al., 2004). Hypericin is reported to localise in different organelles 
depending on the cell type (Table 1.5.3). Moreover, its cellular effect has been associated 
with its localization in mitochondria, Golgi apparatus, endoplasmic reticulum (ER) and 
lysosome. It has been reported the hypericin concentration and incubation time also play a 
role in its position in a cell (Crnolatac et al., 2007; Siboni et al., 2002). We, therefore, 
investigated hypericin’s location within fibroblasts and its association with 3 major 
organelles: ER, Golgi apparatus, and mitochondria.  
The initial experiments determined hypericin location in the cell over a time course as a 
visual confirmation of the uptake assay. All three hypericin concentrations and time points 
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showed hypericin to be localised in the cytoplasm surrounding the nucleus (Figure A.8.1). 
Figure 3.6.1 is a representation image of hypericin in a fibroblast using confocal 
microscopy. At no time or concentration did hypericin enter the nucleus (Figure 3.6.1).  
 
Figure 3.6.1 Representative image demonstrating hypericin’s (Red) general localization was around the 
nucleus (Blue) in the cytoplasm. 
3.6.1. Organelle-specific fluorescent proteins 
3.6.1.1. Endoplasmic reticulum 
The ER serves as centre of protein and lipid synthesis in the cell. In this study, fibroblasts 
were transfected with an ER specific plasmid expressing yellow fluorescent protein. Figure 
3.6.2 displays the ER located perinuclearly and extending throughout the cytoplasm. 
Hypericin-treated cells transfected with this plasmid did not show conclusive colocalization 
between hypericin and the ER (Figure 3.6.2 (C), (D)). However, as colocalization may have 
been obscured by the extensive nature of ER in the cell, a 2 dimensional profile histogram 
for each colour was done to determine any overlap between the ER and hypericin (Figure 
3.6.2). The profile histogram indicated that hypericin staining (red peaks Figure 3.6.2 (E), 
(F)) did not correlate with ER (yellow intensity peaks Figure 3.6.2 (E), (F)) indicating, semi-
quantitatively, no exclusive colocalization between hypericin and the ER. 
3.6.1.2. Golgi apparatus 
The Golgi apparatus, also located in the perinuclear region, is responsible for the processing, 
post-translation modification and transportation of proteins (Campbell & Reece, 2002). 
Plasmid transfection with a Golgi apparatus-specific protein, Rab7WT, was performed. This 
proteins forms part of the protein regulators for vesicle transport and is located in specific 
intracellular compartments such as the Golgi apparatus (Choudhury et al., 2002). Similarly 
to the ER, the Golgi apparatus showed as a diffuse aggregation around the nucleus with 
stronger punctate staining (Figure 3.6.3 (A), (B)). In contrast to the ER location, when 
hypericin was incubated, the punctate staining correlated with the labelled organelle (Figure 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 3: Results 
 
62 
 
3.6.3. (C), (D)). Further analysis of this colocalization profiling displayed 16h hypericin 
treatment accumulates in the Golgi apparatus in primary human fibroblasts (Figure 3.6.3 (E), 
(F)). The scatterplots quantitatively investigated the colocalization by plotting the 
fluorescent intensities of red hypericin (y-axis) and the green fluorescent protein of the Golgi 
apparatus (x-axis) (Figure 3.6.4). This confirmed the results seen in Figure 3.6.3 (E), (F).  
3.6.1.3. Mitochondria 
The mitochondria are the power house of the cell in generating energy rich compounds such 
as adenosine triphosphate (ATP). Mitochondria oscillate between states of fusion and fission 
in the cell. They can appear as tubules in their state of fusion and during fission they are 
independent bean-shaped organelles (Westermann, 2010). 
Mitochondria are known to generate ROS through cellular respiration (Campbell & Reece, 
2002) It has been shown, in other cell types, that hypericin does localise in this organelle and 
is possibly linked to its mechanism of action due to its proximity with oxygen used during 
cellular respiration (Theodossiou et al., 2006). 
Ornithine transcarbamylase is a mitochondrial-specific protein present in the matrix of the 
mitochondria (Davids, 2003). In our system, the cells without hypericin displayed 
mitochondria were in a state of fusion shown by the appearance of tubular-like structures. 
When the cells were treated with 0.25µM hypericin however, there was mild colocalization 
with mitochondria, but not to the same degree as was evident with the Golgi apparatus 
(Figure 3.6.5 (E), (F)). The laser needed to visualise hypericin on the confocal microscope 
was the same yellow laser used in previous experiments in this project (Section 3.2-3.5). 
Unexpectedly, this caused a change in mitochondrial morphology. The mitochondria went 
immediately from the tubular shape to a beaded appearance (Figure 3.6.6 (C-F)). This 
transition was seen only in hypericin treated cells and not in control cells displaying the 
plasmid. This instant change was mostly likely due to the activation of hypericin. It should 
be noted that this state was probably induced by the massive increase in ROS generated by 
activated hypericin. The power of the confocal laser was 250 times more than that used in 
the cell viability, growth curve, scratch and ROS assays. It is important to note that this state 
may not occur in fibroblasts treated with 1J/cm
2
 and 100mW/cm
2
.  
In conclusion, these subcellular experiments show clearly that hypericin localizes to the 
perinulcear region of the cell. It strongly colocalizes with the Golgi apparatus, to a lesser 
extent the mitochondria and has no apparent colocalization with the ER. The high power, 
and therefore high energy density, delivered by the confocal microscope laser caused the 
mitochondria to become segmented, indicating a stress response, in hypericin treated cells. 
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This reaction may be an artefact of the experiment and one must exercise caution to 
extrapolate it as a reaction of the fibroblast to hypericin mediated PDR.  
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Figure 3.6.2 Representative images of fibroblasts transfected with ER-specific YFP plasmid to determine hypericin’s colocalization with this organelle. (A), (B) are fibroblasts with ER plasmid 
(yellow) and the nuclear stain Hoechst (Blue). (C), (D) are fibroblasts treated with 0.25µM hypericin (Red), ER plasmid and Hoechst. (E) is the histogram profile of (C) and (F) is the histogram 
plot of (D). Both (E) and (F) indicate there is no specific colocalization between the peaks of the yellow ER and red hypericin peaks. (n=2) 
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Figure 3.6.3 Representative images of fibroblasts transfected with Golgi apparatus-specific GFP plasmid to determine hypericin’s colocalization with this organelle. (A), (B) are fibroblasts with 
Golgi apparatus plasmid (Green) and the nuclear stain Hoechst (Blue). (C), (D) are fibroblasts treated with 0.25µM hypericin (Red), Golgi apparatus plasmid and Hoechst. (E) is the histogram 
profile of (C) and (F) is the histogram plot of (D). Both (E) and (F) indicate colocalization between the peaks of the green peaks of the Golgi apparatus and red hypericin peaks (arrows). (n=3) 
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Figure 3.6.4 (A), (B) indicated hypericin located in the Golgi apparatus of the fibroblasts. (C), (D) Scatterplots indicating the colocalization of red fluorescent intensities (0.25µM hypericin) on 
the y-axis and green fluorescent intensities (Golgi labelled with GFP) on the x-axis in fibroblasts. 
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Figure 3.6.5 Representative images of fibroblasts transfected with mitochondria-specific GFP plasmid to determine hypericin’s colocalization with this organelle. (A), (B) are fibroblasts with 
mitochondria plasmid (Green) and the nuclear stain Hoechst (Blue). (C), (D) are fibroblasts treated with 0.25µM hypericin (Red), mitochondrial plasmid and Hoechst. (E) is the histogram 
profile of (C) and (F) is the histogram plot of (D). Both (E) and (F) indicate no exclusive colocalization between the peaks of the green peaks of the mitochondria and red hypericin peaks. (n=3) 
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Figure 3.6.6 The mitochondria changed their shape in hypericin treated fibroblasts after irradiation with the confocal microscopes laser. (A, B) Fibroblasts without hypericin have no change in 
their mitochondria after irradiation whereas (C-F) cells incubated with 0.25µM hypericin, their mitochondria changed from a tubular network to have a beaded, fragmented appearance. 
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4. Chapter 4: Discussion 
Photodynamic therapy (PDR) is a relatively new dermatological treatment used to reverse 
the signs of photoageing. It has been successfully used since 2002 (Ruiz-Rodriguez et al., 
2002). There have been several developments and improvements to this therapy over recent 
years. This has resulted in excellent outcomes for many patients. Although a substantial 
body of work has been reported on the clinical outcomes of PDR, there remains a shortfall in 
knowledge about the actual mechanism of PDR, including its in vitro effect on human skin 
cells. Moreover, there is still a need for an ideal protocol where minimal photosensitizer 
(PS) is used and optimised irradiation parameters are defined (Agostinis et al., 2002; 
Kiesslich et al., 2006; MacGregor & Dover, 2010) 
The concept of PDR involves a topically applied PS activated by a specific wavelength of 
light to generate reactive oxygen species (ROS) in the presence of oxygen. Both the PS and 
activating wavelength are integral to the success of the treatment. The PS used in this project 
is hypericin, a photosensitizing pigment compound from the plant Hypericum perforatum (St 
John’s Wort) (Agostinis et al., 2002; Kiesslich et al., 2006). Hypericin is a second 
generation PS offering a high quantum yield for triplet state generation and is, thus, able to 
generate ROS (Agostinis et al., 2002; Berlanda et al., 2010; Kiesslich et al., 2006). It has 
shown promise as a PS in treating various skin conditions such as acne, psoriasis and in 
wound healing (Hager et al., 2009; Kiesslich et al., 2006; Najafizadeh et al., 2012; Oztürk et 
al., 2007). Due to this clinical success, this project investigated its in vitro efficacy in PDR 
on human dermal fibroblasts. 
The purpose of this study was three-fold: firstly, to develop an optimised PDR protocol on 
primary human dermal fibroblasts using three different wavelengths of light to activate 
hypericin. Secondly, hypericin-mediated PDR treatment on fibroblast growth, migration and 
ROS production was determined. Thirdly, hypericin’s subcellular location within fibroblasts 
was shown as this relates to its mechanism of action.  
In line with the first aim of this study, the uptake assay was designed to determine the time 
at which the maximum amount of hypericin was present in fibroblasts. This information was 
important as too low hypericin concentrations would need higher energy and power densities 
to generate enough ROS to cause the PDR reactions and overcompensating with light energy 
and power may result in phototoxic reactions. Moreover, high PS concentrations will lead to 
post-treatment photosensitivity (Avram et al., 2006; Chen et al., 2001).  
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Three hypericin concentrations (0.25µM, 0.5µM and 1µM) were diluted in serum-
supplemented medium and the amount of fluorescence within fibroblasts was quantified. 
These concentrations have been demonstrated to be non-cytotoxic in other cell types (Davids 
et al., 2008). The results showed that using the low concentration of hypericin (0.25µM), 
maximum uptake occurred at 16h. The two higher concentrations (0.5µM and 1µM 
hypericin) peaked at 10h and showed only a slight, non-significant decrease at 16-24h. Our 
results showed a consistent concentration dependence on hypericin uptake. At no time point 
were the three concentrations similar with regards to their fluorescence values (Figure 3.1.1). 
These results were corroborated by microscopy analyses. In addition, micrographs of the 
fibroblasts consistently showed an accumulation in the perinuclear area with fluorescent 
intensity increasing with time (Figure A.8.1).  
Hypericin can enter a cell through various mechanisms. These mechanisms depend on the 
medium in which hypericin is diluted and presented to the cell. In medium without any 
supplement (e.g. fetal bovine serum) this lipophilic compound can diffuse across the cell 
membrane freely (Castano et al., 2004). This method has been documented to be the fastest 
way for hypericin to enter a cell (Crnolatac et al., 2007; Siboni et al., 2002). The higher the 
extracellular hypericin concentration, the faster the rate of diffusion (Buriankova et al., 
2011). Another mechanism of entry is hypericin bound to serum proteins such as low-
density lipoprotein (LDL) and Human Serum Albumin (HSA) (Buriankova et al., 2011; Das 
et al., 1999; Gbur et al., 2009; Huntosova et al., 2010; Kascakova et al., 2005; Mukherjee et 
al., 2008; Roelants et al., 2011; Siboni et al., 2002; Uzdensky et al., 2001). The serum 
protein that hypericin is bound to will ultimately determine its mechanism of entry into a cell 
and its final location. When it is attached to the serum protein it can enter a cell via 
endocytosis (hypericin associated with LDL) or pinocytosis (hypericin associated with HSA) 
(Siboni et al., 2002). The different mechanisms affect the time taken for hypericin to enter 
the cell. Some authors have suggested that incubation of hypericin with serum supplemented 
medium causes competition between LDL-mediated hypericin uptake and passive diffusion 
(Crnolatac et al., 2007). 
Our results correlate with the serum-protein mediated uptake of hypericin into the cell. 
Hypericin’s uptake peaked at 10-16h which is far longer than faster diffusion rates reported 
in the literature (2-3h) (Crnolatac et al., 2007; Siboni et al., 2002). In this study, hypericin 
was shown to be located in the Golgi apparatus of fibroblasts and correlates with the LDL 
mechanism of entry into the cell following endocytosis of the LDL receptor. 
An important consideration in hypericin’s uptake is its potential to form aggregates. 
Hypericin aggregates are non-fluorescent and occur when hypericin is in an aqueous 
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solution or at high concentrations (10µM<) (Kascakova et al., 2005). Once inside the cell, 
the aggregates are believed to separate into single compounds (Buriankova et al., 2011). 
This is a point of concern in that aggregates result in self-quenching where not only the 
quantum yield is lower, thus affecting ROS generation, but the fluorescent signal decreases 
as well (Buriankova et al., 2011; Gbur et al., 2009; Theodossiou et al., 2004). These 
aggregates make it difficult to use hypericin’s autofluorescence and relate it to its 
concentration. When aggregates are present the concentration, interpreted through its 
fluorescent intensity, will appear lower than its real value (Buriankova et al., 2011; 
Huntosova et al., 2010; Kascakova et al., 2005; Theodossiou et al., 2004). However, as we 
were not looking for an exact quantification but rather determined at what time maximum 
hypericin uptake occurred relative to other incubation times, this method served our purpose. 
In addition, over long periods of time a decrease in hypericin’s fluorescence has been 
documented in other cell types which was attributed to aggregate formation (Buriankova et 
al., 2011; Huntosova et al., 2010; Theodossiou et al., 2004). At no time in this experiment 
did the fluorescence of hypericin decrease, indicating a distinct lack of aggregation 
formation.  
Hypericin incubation time of 16h was used for all further experiments. This time was the 
most practical in PDR for all three hypericin concentrations and correlated with literature 
(Berlanda et al., 2010; Hendrickx et al., 2005). Once the time for maximum uptake was 
defined, a non-cytotoxic, irradiation protocol was determined for three different activating 
wavelengths of light.  
PDR has the potential to generate high levels of ROS which can overwhelm the cell, leading 
to its death. It is, therefore, important that the protocol established in this project had no 
negative effects on cell survival. To this end we used the XTT cell viability assay (Section 
2.2) to find a PDR protocol that was non-cytotoxic to fibroblasts. This assay is based on 
viable cellular metabolism resulting in the colorimetric conversion of tetrazolium salt from 
yellow to orange via mitochondrial enzymes. In establishing our PDR protocol, two 
variables were analysed - hypericin concentration and the irradiation protocol.  
As hypericin stock solutions are dissolved in DMSO, we noted the effect of this diluent on 
the cells. It was found to have no effect on cell viability which is in line with the literature 
where >1.25% is considered cytotoxic (Berlanda et al., 2010). Dark cytotoxicity of hypericin 
in the literature ranges from 3.13µM, 31.5µM and 250µM in human epidermoid carcinoma 
cell line A431, colon adenocarcinoma and murine keratinocytes, respectively (Berlanda et 
al., 2010; Theodossiou et al., 2004; Uzdensky et al., 2001). This indicates a cell type 
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dependence on hypericin tolerance without light activation. In this project the highest 
hypericin concentration (1µM) showed no dark cytotoxic effects on fibroblasts. 
Next we investigated the three hypericin concentrations (0.25µM, 0.5µM and 1µM) 
activated by three different wavelengths of light. The specific wavelengths of light were 
delivered by two types of light sources: lasers and lamps. Two solid state lasers were used, 
one emitted a continuous wave light at 561nm (yellow colour) and the other at 635nm (red 
colour). In using a laser, all three variables from Equation 1.4.1 (Section 1.3.1.1) can be 
controlled or altered. A laser allows for an exact irradiation protocol, regarding all three 
variables, to be optimised whereas when using a lamp only energy density and time can be 
changed (Pryor et al., 2011).  
It is common to test the efficacy of different PS with several wavelengths of light (Bjerring 
et al., 2009; Blank et al., 2002; Clementoni et al., 2010; Kubin et al., 1996). It has been 
reported that different wavelengths used in PDR can treat different aspects of photoageing 
(Bjerring et al., 2009; Ruiz-Rodriguez & López-Rodriguez, 2006). Three wavelengths 
(635nm- red, ~365nm - UVA, 561nm - yellow) were chosen as each provides a benefit in 
treating skin conditions and/or activating hypericin.  
Besides photorejuvenation, red light has been used in dermatology to treat other skin 
conditions including diabetic and chronic wounds (Abrahamse & D, 2009; Houreld & 
Abrahamse, 2007; Peplow, Chung, & Baxter, 2012a,  2012b). Its advantage of deep 
penetration into the skin (Agostinis et al., 2011; MacGregor & Dover, 2010; Peng et al., 
2008) allows for the light to not only affect the epidermal cells but also the fibroblasts 
situated deeper in the dermis.  
Three energy densities delivered by the red laser light were used to activate the three 
hypericin concentrations. A significant increase in cell viability was seen 24h after treatment 
when fibroblasts were pretreated with 0.25µM and 0.5µM hypericin and irradiated with 
2.5J/cm
2
red light (Figure 3.2.1). Overall, it appears that hypericin activated by red light had 
minimal effect in fibroblasts. In addition, there was a threshold affect where the therapy 
changed from being ineffective at low energy densities to increasing cell viability at higher 
energy densities. However, at the highest energy density (5J/cm
2
) the therapy showed no 
change in cell viability. This indicates that ROS levels could have changed from being 
beneficial to causing an upregulation of the antioxidant system where ROS are scavenged. 
These results point to a potential threshold level of activation where a range of red light 
energy is effective.  
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Red wavelengths of light have been shown to increase fibroblast proliferation and their 
activity in the wound bed (De Sousa et al., 2010; Houreld & Abrahamse, 2007; Peplow et 
al., 2010; Peplow, Chung, & Baxter, 2012a). PDR therapy that used IPL (550nm-1200nm) 
had great success in treating the global appearance of photoageing and fine lines, and to 
lesser extent mottled pigmentation and roughness (Table 1.5.1). It is interesting to note that 
the two most commonly used PS, ALA and MAL, only absorb approximately 10% of red 
light yet still result in satisfactory outcomes according to most patients and clinicians (Gold 
& Goldman, 2004; Haddad et al., 2011; MacCormack, 2008; Peng et al., 1997) (Table 
1.5.1). Interestingly, hypericin absorbs only up to 33% red light (Figure 1.5.2), yet we do not 
see the positive effects as demonstrated with ALA and MAL in other PDR protocols. 
Despite this, the potential of using red light in PDR is enticing due to its penetrating depth 
and relative availability in dermatological clinics (Agostinis et al., 2011; Peng et al., 2008). 
It would appear that red light activation of hypericin, under these co ditions, had a small 
effect on cellular activity of the fibroblasts. Potentially increasing the power density, thereby 
increasing the energy density, may result in a different outcome and should be considered in 
the future.  
UVA light (~365nm) was the next wavelength investigated. UVA wavelengths can penetrate 
into the skin to the upper dermal layer (Pillai et al., 2005). Moreover, hypericin has two 
major peaks in its absorption spectra with one being in the UVA range (Figure 1.5.2). A fine 
line exists between UVA being beneficial in generating low levels of ROS in PDR on the 
one hand and being cytotoxic on the other. UV radiation from sunlight, which is composed 
of UVA and UVB wavelengths of light, is the main effector in photoageing and has been 
linked to carcinogenesis (Fisher et al., 2008; Halliwell & Gutteridge, 2007c; Macfarlane, 
1992; Pillai et al., 2005). This, thus, highlights the need to fully optimise the irradiation 
protocol so a mi imum amount of energy is used to maximally activate the PS to generate 
low ROS levels.  
The three hypericin concentrations (0.25µM, 0.5µM and 1µM) were activated with 0.5J/cm
2
 
and 1J/cm
2
 of UVA. The lower concentrations of hypericin had no effect or a slight increase 
in cell viability, whereas 1J/cm
2
 hypericin had a significant decrease in cell viability at the 
high hypericin concentration (1µM) (Figure 3.2.2). Similar to red laser light, where an 
increase in cell viability occurred at 2.5J/cm
2
 with 0.5µM hypericin, UVA light showed an 
increase with a low energy density of 1J/cm
2
 and low 0.25µM hypericin concentration. This 
is due to hypericin’s ability to absorb more of UVA’s light energy compared to red light. By 
effectively absorbing energy, a similar level of ROS was generated with less energy and 
lower PS concentrations but resulted in the same positive cellular effect. A threshold for cell 
viability was seen again, as noted with the red laser, where high hypericin concentrations 
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and high energy resulted in a decrease in cell viability but low energy and low hypericin 
concentrations resulted in an increase. 
It would seem counterintuitive to use UVA in PDR seeing that UV radiation is the main 
agent in the development of the signs of skin ageing (Fisher et al., 1997,  2002; Pillai et al., 
2005; Rittié & Fisher, 2002). However, there are many therapies to date that use UVA to 
treat skin conditions. Examples include, psolarens and UVA (PUVA) therapy to treat 
vitiligo, psoriasis, T-cell lymphoma and acne vulgaris (McEvoy & Muller, 1992; Mosher et 
al., 1992; Satra & DeLeo, 1992). However, these therapies are used within established 
dermatological institutions where the patients are constantly monitored. 
The third wavelength investigated was yellow light, specifically 561nm. Hypericin 
maximally absorbs light with a wavelength of 563nm and we were able to use a laser which 
emits light at 561nm. We, therefore, could activate hypericin to its full potential. Kubin et al 
reported activating hypericin with different wavelengths and found 532nm light was more 
efficient at photosensitization of hypericin treated human skin than 630nm (Kubin et al., 
1996). This indicates hypericin’s high energy absorption of this range of wavelengths and 
subsequent high level ROS generation under a specific irradiation protocol. This is in 
agreement with results reported in this project. 
We investigated the effect of yellow laser light activation of hypericin on fibroblasts using 3 
different power densities in a similar manner to Head et al (Head et al., 2006). Three energy 
densities were used with each power density as seen in Figure 3.2.3. Very low energy 
densities (0.1J/cm
2
, 0.25J/cm
2
, 0.5J/ cm
2
) were used with the lowest power density 
(10mW/cm
2
). However, these low energy densities had the same irradiation time as those 
energy densities used with higher power densities. This allowed us to investigate if exposure 
time had any effect on cell viability (Table 2.4.1). There was little change among the three 
hypericin concentrations irradiated with 10mW/cm
2
 light at any of the energy densities. 
However, 0.25µM hypericin showed an increase in viability when irradiated with 0.25J/cm
2
. 
At higher energy densities with a power density of 50mW/cm
2
, there was a hypericin 
concentration and energy density-dependent decrease in cell viability. This decrease was 
somewhat mirrored at the higher power density of 100mW/cm
2
. At the highest power 
density (100mW/cm
2
), however, there was an increase in cell viability with the lowest 
energy density (1J/cm
2
) and 0.25µM hypericin. 
It, therefore, appears juxtaposed that both the low and high energy and power densities 
would result in an increase in viability. Regarding the low energy and power density 
(0.25J/cm
2
, 10mW/cm
2
), this may be due to the longer irradiation time resulting in more 
hypericin being activated and reacting within the cell. In contrast, the short burst of high 
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power delivering a small amount of energy in a short time could result in a similar ROS 
generation but may elicit a different signalling pathway. Both protocols appear to result in a 
positive outcome. 
Consistently, when cells were irradiated with yellow laser light, the 0.25µM hypericin 
concentration caused an increase in cell viability. This activated hypericin concentration 
most likely generates low levels of ROS which have a positive impact on the cell. 
Green/Yellow light alone has been shown to have an advantageous effect on fibroblast 
proliferation at 24h (Vinck et al., 2003). This wavelength, therefore, has benefits similar to 
red and UVA light where it has shown positive outcomes with regard to increased cell 
proliferation. Yellow light is able to penetrate between 1 - 1.6mm into tissue (Nootheti & 
Goldman, 2006; Peng et al., 2008). It is, therefore, possible that yellow light can activate 
hypericin in the papillary dermis as the epidermis has a thickness of about 0.1mm depending 
on the location in the body (Blank et al., 2002; Gambichler et al., 2006). Blank et al reported 
the potent in vivo effect of hypericin activated with 550nm and 590nm light in mouse skin. 
Although this treatment was PDT-mediated tumour destruction, it highlighted that the depth 
of tissue response to activated hypericin was about 10mm, far beyond the predicted depth of 
1mm reported for 550-590nm light (Blank et al., 2002). This further emphasises how 
successful yellow light is in activating hypericin to the level of the dermis. Yellow light 
activation has indirectly been reported with other PS with PDR therapies using IPL systems, 
which include the yellow range of wavelengths (550nm-1200nm), and have been successful 
in resolving the signs of photoageing (Table 1.5.1). 
It is important to note that many PDR therapies have not been optimised with regards to the 
specific wavelength activation of the PS or energy and power densities as demonstrated in 
the variety of protocols represented in Table 1.5.1. In this work we demonstrate a threshold 
where activated hypericin changes from being beneficial to cytotoxic. This is an important 
contribution to future hypericin mediated PDR and is often not demonstrated in other PDR 
studies.  
As the cell viability assay indicates mitochondrial function, an increase could mean two 
things: an increase in proliferation or mitochondrial activity. An increase due to proliferation 
would indicate the therapy has had an effect on the growth rate of the cells. Alternatively 
mitochondrial activity could signify that the cells may not have increased in number, and 
may in fact have decreased, but their collective activity or cellular metabolism is higher than 
the control cells. To investigate whether this increase was due to an increase in proliferation 
rate, growth curves for each wavelength of light were performed over a period of 7 days.  
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In investigating PDR’s effect on growth, the protocol which gave the greatest increase in the 
cell viability for each wavelength was used for a growth curve. In the case of red light, 
0.5µM hypericin was irradiated with 2.5J/cm
2 
(Figure 3.3.1). The growth rate of the red laser 
light-PDR treated cells was not significantly different to control cells. An issue for this 
growth curve was that the power density was not the same as the cell viability assay. Due to 
the practical limitations of laser, the highest power output was used for the growth curve and 
the power density was calculated retrospectively. Interestingly, there was a lag in growth 
between day 1 and 3. This could be due to the long irradiation times (16min for each well) 
for this specific wavelength that might have stressed the cell causing a slowing in 
proliferation. When the growth curve with 0.5J/cm
2
 UVA and 0.25µM hypericin was 
performed, there was a lag between the normal control and the PDR treated cells (Figure 
3.3.2). A similar outcome was noted when 0.25µM hypericin was activated by 1J/cm
2
 
(100mW/cm
2
) yellow laser light (Figure 3.3.3). In both cases the slowi g in growth was not 
permanent and the cells regained a rate of proliferation similar to the control cells after a few 
days. In addition, the yellow laser growth curve included cells that irradiated with the 
vehicle (0.0125% DMSO) only. The irradiated cells had a similar growth pattern to the PDR 
treated cells where there was a slight reduction in the growth rate of the fibroblasts. This 
indicates the light itself could have an effect which is resolved and the normal growth rate 
returns (as compared to the control). Interestingly, some reports have shown that hypericin 
on its own, without light activation, can slow down the proliferation of fibroblasts (Oztürk et 
al., 2007). Noteworthy, is that the red laser and UVA light activation growth curves were 
repeated once with an intra-triplicate repeat. In contrast, the growth curve with hypericin 
activated by yellow laser light was repeated in three individual experiments. For these data 
to be confirmed, more replicates would need to be done for the other wavelengths. 
Unfortunately, we only had limited access to these light sources (UVA transilluminator and 
red laser), therefore, could not repeat these experiments within the time frame of this project. 
We would, therefore, need further testing to verify these results. 
Here, it seems that the ROS generated by PDR may cause a slight slowing in cell growth 
which disappears after a few days. Interestingly, the opposite response is generally reported 
where ROS is associated with proliferation (Halliwell & Gutteridge, 2007a). In our case, 
however, this contradiction is likely due to the PDR protocol used. Our main aim was to 
generate a non-cytotoxic PDR protocol on primary human fibroblasts and not necessarily 
affect the proliferation rate of fibroblasts. Furthermore, this also indicates these protocols 
will most likely not cause a hyperproliferative state in fibroblasts. Hyperproliferation is 
linked with fibrosis where an unregulated, overproduction of collagen occurs as in the case 
of  keloid scarring (Halliwell & Gutteridge, 2007a; Lim et al., 2001; Murrell et al., 1990). In 
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addition, results from our scratch assay show a change in cell morphology after PDR 
treatment. The change in shape from long and spindle to a shorter, rounded shape indicate 
the cells are not in a proliferative state (Murrell et al., 1990; Oztürk et al., 2007). This non-
significant growth inhibition could be linked with the fibroblast’s antioxidants systems 
scavenging the ROS and causing an overall slowing of proliferation as was highlighted in 
the study by Murrell et al (Murrell et al., 1990). Moreover, experiments using “low dose 
PDT” with hypericin indicate cellular growth arrest and suggest it is caused by alterations to 
signalling molecules such as the anti-apoptotic protein Bcl-2 and cycle regulator protein 
cyclin-dependent protein kinase 1 (CDK-1) (Piette et al., 2003; Vandenbogaerde et al., 
1998). An alternative interpretation could be that the cell is funnelling energy towards other 
metabolic processes. Two studies have shown that fibroblast proliferation and collagen 
synthesis are mutually exclusive when regulated under combinations of various cytokines 
such as TGF-β, connective tissue growth factor (CTGF) and epidermal growth factor (EGF) 
(Grotendorst et al., 2004; Varga et al., 1987). We propose that the metabolic process 
upregulated may be collagen synthesis. This correlates with the results seen in the scratch 
assay.  
As the growth rate did not change after treatment, the increase in cell viability indicates a 
possible increase in other cellular activities. Cellular reactions of fibroblasts in late wound 
healing regarding collagen synthesis and remodelling are similar to those in skin 
rejuvenation regarding collagen neogenesis and the breakdown of the fragmented ECM 
through MMP (Fisher et al., 2008; Grotendorst et al., 2004; Varga et al., 1987; Welch et al., 
1990). Furthermore, it has been shown that fibroblast migration occurs mutually exclusively 
from collagen synthesis in the wound healing sequence (Singer & Clark, 1999; Welch et al., 
1990).  
The scratch assay was used to determine the rate of wound closure and, therefore, the speed 
of cell migration after PDR treatment. The cells are blocked from entering mitosis with a 3h 
incubation with mitomycin C which stops DNA synthesis. This allows migration to be 
analysed without the effect of proliferation. Only one time point (24h from initial scratch) 
was assessed as multiple photographs exposed the cells to bouts of light that could 
potentially reactivated hypericin.  
Interestingly, the yellow laser-irradiated hypericin-treated fibroblasts only migrated 22% 
compared to 54% wound closure of the control cells. The other controls in the experiment, 
hypericin or irradiated only, fibroblasts migrated at the same rate as the control cells. This 
indicates that neither hypericin nor light irradiation on its own had an effect on migration. 
The difference in wound size between the control and the PDR treated cells was obvious in 
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the photographs (Figure 3.4.1). This correlates with other studies investigating activated 
hypericin’s inhibitory effect on migration (Buytaert et al., 2008; Hendrickx et al., 2005; 
Martínez-Poveda et al., 2005; Zhang et al., 1997). However, it should be noted that this 
results stem from a 2 dimensional interpretation of fibroblast function. As fibroblasts 
function is dependent on its attachment to the matrix, these results may differ when cells are 
treated within a 3D matrix (Varani et al., 2004; Welch et al., 1990). The other wavelengths 
were not analysed as we did not have access to them at the time these experiments were 
being performed.  
These results, along with the growth curve data and wound healing literature, could suggest 
that when cells are not growing or migrating they are actively producing matrix proteins due 
to an increase in activity (Grotendorst et al., 2004; Oztürk et al., 2007; Singer & Clark, 
1999; Varga et al., 1987; Welch et al., 1990). On the basis of our data, we propose that due 
to the slowing of proliferation and inhibition of migration, fibroblasts after PDR treatment 
are funnelling metabolic energy to other processes, such as collagen synthesis. This theory 
was supported by Oztürk et al where hypericin treated cells resulted in a slowing of 
proliferation and the formation of collagen granules in fibroblasts (Oztürk et al., 2007).  
Reactive oxygen species (ROS) are thought to be the main effector in PDR. As in skin 
ageing, ROS stimulates pathways and cytokines to be released to effect changes in cellular 
metabolism. A ROS assay was performed to confirm that ROS generation had, indeed, 
occurred after PDR treatment. This would support the fact that all changes demonstrated in 
the previous experiments were related to ROS produced by PDR and not solely by the light. 
In this assay a dye (DCF-DA) was used that once oxidised, fluoresces green, and detects 
various ROS (Halliwell & Gutteridge, 2007b). Two methods were used to analyse ROS 
production in the cells. The first method used flow cytometry to analyse the fluorescence 
within each individual cell and the second employed a 96-well based assay where the cell’s 
fluorescence was determined using a fluorimeter. Both methods proved successful. 
In using the two methodologies, it was shown that irradiated hypericin caused an increase in 
ROS in human dermal fibroblasts. Yellow and UVA light alone showed low ROS levels in 
comparison to the activated hypericin-treated cells. The ROS levels generated were not at 
overwhelming or cytotoxic levels as the PDR protocol was exactly the same as the cell 
viability assay where no cell death occurred. In addition, we showed that the protocol is 
indeed generating ROS and that the results are most likely not from the light irradiation 
alone. Low level ROS has been shown to be beneficial and affect signalling pathways in the 
cell to elicit positive reaction such as an increase in cellular activity (Halliwell & Gutteridge, 
2007a; Lubart et al., 2005,  2007).  
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Although the results gave the same conclusion, there were differences between the two 
methods’ values. The flow cytometry method showed yellow laser light activated hypericin 
generates ROS 96±23.55% higher than basal where in the fluorimeter based assay the 
increase was only 42%±75.54. When UVA-irradiated hypericin was tested, the increase in 
ROS using flow cytometry was 186%±22.66 compared to 56%±53.82 using the fluorimeter. 
These differences between the two methods may be due to several reasons. Firstly, due to 
the nature of primary fibroblasts cultured from different patients used in each method, an 
inherent genotypic variation may account for the cell’s response to activated hypericin. 
Secondly, the power density differences between 2 methods (irradiating 35mm dish and well 
in a 96-well plate), and the time of exposure differences, would have had an impact on the 
result. Finally, during the flow cytometric method it is most likely that the collection of cells 
through trypsinization, subsequent washes and resuspension in PBS could stress the cells, 
raising the levels artificially (Halliwell & Gutteridge, 2007d). However, the individual cell’s 
fluorescence determined via flow cytometry is, perhaps, more accurate as it is a mean 
fluorescent signal from each individual cell compared to an overall fluorescence reading 
from a well of a plate.  
When hypericin is irradiated it mainly generates singlet oxygen in an oxygen-dependent 
photochemical type II reaction (Agostinis et al., 2002; Kiesslich et al., 2006). Other ROS, 
such as superoxide anion, and hypericin radicals are also generated in similar photochemical 
reactions but to a lesser extent (English et al., 1999; Gbur et al., 2009). The intrinsic lifetime 
of singlet oxygen in a lipid environment is 13– 35µs and about 4µs in pure water (Buytaert 
et al., 2007; Gbur et al., 2009). This extremely short time makes detection of this ROS very 
difficult and needs specialised instruments such as spin trapping coupled with electron 
paramagnetic resonance spectroscopy (Lubart et al., 2007). When ROS, such as singlet 
oxygen, are metabolised in the cell, hydrogen peroxide is generated. For this reason, DCF-
DA was used and its green fluorescent emission made it an excellent choice as there was no 
overlap in spectral readings between it and hypericin.  
As important as confirming ROS production, the location of the PS within the cell is 
intimately linked with PDR’s mechanism of action. The subcellular location of hypericin 
closely relates to the area in which ROS can react (Huntosova et al., 2010; Siboni et al., 
2002; Uzdensky et al., 2001). It has been suggested that the biological photosensitization 
and cellular uptake of a PS and its final location can be more relevant to its efficacy than its 
basic photophysical properties (Siboni et al., 2002).  
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We investigated hypericin’s location in primary human dermal fibroblast after 16h 
incubation of hypericin in complete (serum supplemented) medium and its colocalization 
within three major organelles.  
The three organelles investigated were: ER, Golgi apparatus and the mitochondria. Each 
organelle provides a specific and vital function within the cell. The ER is involved in protein 
and lipid synthesis in the cell (Campbell & Reece, 2002; Sherwood, 2010). The ER has a 
lower antioxidant concentration than other organelles in the cell. This provides an optimum 
redox state for ER-specific enzymes to catalyse the disulphide bridges needed for protein 
folding (Halliwell & Gutteridge, 2007e). The proteins are modified in the ER and leave in 
transport vesicles to the Golgi apparatus. The Golgi apparatus is involved in sorting, storing 
and moving these proteins to different locations in and out of the cell (Campbell & Reece, 
2002). The mitochondria are the power houses of cell, generating the energy in the form of 
adenosine triphosphate (ATP) (Campbell & Reece, 2002). Mitochondria have been 
associated with the ageing process since 1956 (Halliwell & Gutteridge, 2007c). ROS 
produced for secondary signalling by the mitochondria or by errors in oxidation 
phosphorylation lead to oxidative damage and, eventually, the signs of ageing (Halliwell & 
Gutteridge, 2007c; Ma et al., 2001).  
In this study it was found that hypericin colocalized with the Golgi apparatus and to a lesser 
degree within the mitochondria. Interestingly, hypericin was not found to colocalize within 
the ER. It has been suggested that the membranes of intracellular organelles, such as the 
Golgi apparatus and mitochondria, can serve as a pump extracting hydrophobic molecules 
like hypericin from a weak solution and keeping them at a low cytosolic concentration 
(Uzdensky et al., 2001). The uptake of hypericin was a slow process, therefore, the long 
time needed for hypericin’s uptake emphasises that hypericin’s entry into the cell may be 
due to its association with HSA or LDL (Uzdensky et al., 2001). Interestingly, other authors 
have shown different hypericin incubation times result in different subcellular locations 
(Siboni et al., 2002; Vuong et al., 2011). In addition, in all experiments hypericin was not 
found in the nucleus. As ROS only acts within a small area, any ROS generated during PDR 
will most likely not affect the DNA. This is beneficial as the therapy has a small chance of 
becoming genotoxic. This re-iterates that the use of hypericin has to be complemented with 
an optimised PDR protocol. 
Mitochondria in fibroblasts used in this project appeared as long fibrils in the primary 
human fibroblasts. Mitochondria appear differently in different cell types but most 
commonly in organised fibrils (Westermann, 2010). For example, the mitochondria appear 
as granules in WiDr cells, as granules and fibrils in NHIK cells, and mostly as fibrils in 
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glioblastoma cells D54Mg (Uzdensky et al., 2001). Although their function is mainly to 
produce ATP for cellular metabolism, mitochondria are indispensable for the citric acid 
cycle, β-oxidation of fatty acids, haem synthesis and an initiator of apoptosis (Westermann, 
2010) 
Visualization of hypericin on the confocal microscope led to the power being approximately 
250 times higher than in previous experiments (Section 3.2-3.5). The irradiation led to an 
instant change in the mitochondrial morphology from fibrils to a more beaded shape (Figure 
3.6.6). This drastic change in shape was unexpected and novel. A reasonable explanation for 
it though, is that it is related to the state of fusion and fission (Westermann, 2010). 
Mitochondria exist in a state of fusion in the cell and this is often seen microscopically as 
fibrils. This allows the mitochondrion’s outer membranes to fuse with one another allowing 
for quick communication and dissipation of metabolic energy (Westermann, 2010). Fission 
is evident during cell division and apoptotic events. As the activation of hypericin resulted in 
high levels of ROS, it is likely that the fission seen in our samples is related to apoptosis as 
there are links with dissociating mitochondria and this form of cell death (Westermann, 
2010).  
It must be said that the changes seen in the mitochondria of the fibroblasts are probably not 
seen during the PDR treatment under the protocol established in this project. The changes 
were due to the high power and are not representative of mitochondrial morphology during 
PDR.  
Studies have shown that activated PS located within the ER generate a high level of free 
calcium which in turns causes a release of cytochrome c from the mitochondria and initiates 
programmed cell death – apoptosis (Buytaert et al., 2007; Castano et al., 2005). Hypericin at 
a low dose has been shown to modulate calcium but is not related to cell death (Pfaffel-
Schubart et al., 2006; Piette et al., 2003). It is, therefore, advantageous that hypericin is not 
located in the ER with our protocol as it is not likely to trigger apoptosis through this 
mechanism. A PS located within the mitochondria cause an uncoupling of the oxidative 
phosphorylation chain leading to necrosis. In addition, damage to the mitochondria can 
trigger apoptosis via various signalling molecules and pathways as reviewed in several 
papers (Almeida et al., 2004; Buytaert et al., 2007; Castano et al., 2005). In this regard, it 
should be treated with caution that hypericin mediated PDR may affect the mitochondria. 
However, due to that fact that cell viability was not decreased in earlier experiments, this 
most likely does not occur in our protocol. There is scant information regarding the Golgi 
apparatus’ involvement in PDR treatment. MAP kinases are also targeted by activated 
hypericin however, the specific proteins upregulated and phosphorylated appears to be cell 
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type and protocol dependent (Assefa et al., 1999; Buytaert et al., 2006; Hendrickx et al., 
2005; Pfaffel-Schubart et al., 2006; Piette et al., 2003). It appears that the PS concentration 
and irradiation protocol are extremely important and the incorrect PDR treatment will tip the 
cells towards a catastrophe rather than having a beneficial effect through altering 
intracellular signalling cascades (Assefa et al., 1999; Buytaert et al., 2006; Kiesslich et al., 
2006; Piette et al., 2003).  
To this end, the in vitro experiments in this project lay the foundation for future hypericin-
mediated PDR. This project shows the location of hypericin within the cell, and an increase 
in cell viability, which indicates the protocol used here most likely will not have negative or 
cytotoxic events and may push the cell towards collagen production.  
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5. Chapter 5: Conclusion and Future Directions 
5.1. Conclusion  
Photodynamic therapy (PDR) is a relatively new therapy used to treat the signs of ageing. 
However, an established protocol which gives consistent results does not exist (Table 1.5.1). 
In addition, little is known about the molecular mechanism of this treatment regime (Table 
1.5.2). The main objective of this project, therefore, was to optimise a protocol based on 
PDR using the photosensitizer (PS) hypericin and characterise its effects on primary human 
dermal fibroblasts. These cells were chosen as they are the chief cell type in the dermis 
where some of the most prominent signs of ageing occur. 
In determining the time for maximum cellular uptake of the PS, three hypericin 
concentrations were tested. Hypericin’s uptake will ultimately decide its final location in the 
fibroblasts and its mechanism of action during PDR treatment. It was found that hypericin 
reached a maximum concentration after 16h for the lowest concentration (0.25µM) and 10h 
for both 0.5µM and 1µM hypericin. Ultimately, 16h incubation time was decided upon as 
there was not a significant difference between 10 and 16h with the higher concentrations 
(0.5µM and 1µM) and this time was in agreement with the literature (Berlanda et al., 2010; 
Hendrickx et al., 2005).  
Three different wavelengths of light were utilized to activate hypericin in this project. 
Moreover, different energy and power densities were used for each wavelength. These 
wavelengths are linked to the absorbance spectrum of hypericin and are related to the 
manner in which this compound captures different wavelengths of light (Figure 1.5.2). All 
the wavelengths displayed an increase in cell viability with low hypericin concentrations 
(0.25-0.5µM). Once a hypericin concentration and irradiation protocol was decided upon for 
each wavelength, we sought to characterise its effect on the fibroblasts. 
The increase in cell viability could relate to an affect on the proliferation rate or cellular 
activity. We investigated its effect on growth and showed PDR treatment did not affect the 
proliferation of fibroblast with any of the wavelengths and their associated hypericin 
concentration. We investigated cellular activity through a scratch assay to determine if the 
migration rate of the fibroblasts was affected. We found that yellow laser light activation of 
hypericin significantly decreased the rate of wound closure compared to the control 
fibroblasts. As reactive oxygen species (ROS) is believed to be the main mediator in altering 
signalling toward rejuvenation in PDR, we confirmed that ROS was being generated through 
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this therapy using the oxidation-sensitive dye, DCF-DA. Both yellow laser and UVA light 
activation of 0.25µM hypericin caused an increase in ROS.  
Taken together these results show hypericin used in PDR did not affect the growth rate of 
cells, instead inhibited the migration of the cells and resulted in an immediate, non-toxic 
increase in ROS production.  
Finally, we sought to uncover hypericin’s location within the fibroblast and its colocalization 
with major cellular organelles. Hypericin colocalized to the Golgi apparatus and to a lesser 
degree to the mitochondria. Interestingly, hypericin was not found in the ER or the nucleus. 
This was considered advantageous as ROS generated in the ER could cause free calcium to 
leak from the organelle initiating apoptosis. In addition, its absence in the nucleus would not 
result in genotoxic mutations of DNA in the nucleus. Partial colocalization with the 
mitochondria should be raised as a point of concern as this organelle is linked with inducing 
apoptosis and necrosis if the ROS levels are too high.  
This work underlines the importance of in vitro characterization of PDR therapy as 
inappropriate hypericin concentrations and irradiation protocol result in a decrease in viable 
cells (Section 3.2) and further detrimental effects. 
Overall this optimised protocol shows PDR using hypericin has the potential to cause an 
increase in cellular activity. This increase in activity could be an upregulation of cellular 
metabolism resulting in regulation of the ECM as demonstrated in other studies (Najafizadeh 
et al., 2012; Oztürk et al., 2007). This would require further investigation into the gene and 
protein expression levels of dermal matrix proteins and characterization in other skin cell 
types. 
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Figure 5.1.1 The diagram represents a summary of the work reported in this dissertation. 
Hypericin (seen here as red dots) moved into the cell and was mainly located in the Golgi 
apparatus and to a lesser degree in the mitochondria. Hypericin was not seen exclusively in the 
endoplasmic reticulum (ER). When hypericin was irradiated with the three different 
wavelengths of light reactive oxygen species (ROS) were generated. The effects of this PDR 
therapy are reported on the right-hand side of this diagram where an increase of mitochondrial 
function was noted with all three wavelengths. There was no effect on growth when PDR was 
performed. Yellow laser light activated hypericin resulted in an inhibition of fibroblast 
migration and hypericin irradiated with yellow laser and UVA light resulted in non-cytotoxic 
levels of ROS being formed. Overall, the hypericin activated with yellow laser shows promise as 
a PDR treatment.  
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5.2. Future Directions and Considerations 
The work from this project forms a strong base in establishing a PDR protocol using 
hypericin. While there is still much work to be done before hypericin mediated PDR could 
be considered viable for clinical applications, the data presented here makes a compelling 
case for hypericin-mediated PDR to be considered as a strong candidate in cosmetic biology.  
Human skin fibroblasts were the only cell type used in this research. However, 
investigations following the same rationale could be employed on the other two major skin 
cell types i.e. keratinocytes and melanocytes. Furthermore, a three-dimensional model 
representing all three cell types would be ideal as this would simulate an in vivo situation. In 
this scenario, fibroblasts are seeded into collagen matrices simulating the dermis and 
keratinocytes and melanocytes seeded together to form a stratified layer on top of the matrix 
in a similar manner to the epidermis. In this way paracrine signalling between the cells could 
occur during and after PDR treatment. In addition, an environment where fibroblasts can 
attach to the ECM may give a more realistic view of what may occur in the skin. This is due 
to the fibroblasts, not only being stimulated through signalling cascades, but through their 
mechanosensing attachment to the matrix affecting their metabolism. 
To fully elucidate the molecular mechanism behind PDR treatment using hypericin analysis, 
ECM genes and proteins would need to be determined at several time points in three skin 
cell types, individually or combined in a 3 dimensional model. Initial candidates for analyses 
include: collagen type I and MMP-1. Transient alterations in collagen synthesis and active 
MMP secretions would contribute to the elucidation of PDR treatment and, thus, illuminate 
novel rejuvenation processes. Both collagen type I and MMP-1 are secreted proteins and, 
thus, cell lysates cannot be used for their analysis via western blots. However, procollagen 
could be detected from cell lysates and this would relate to overall collagen synthesis. 
Serum-free conditioned medium would be used for MMP-1 detection. Furthermore, 
zymography could be used to confirm the activity of this enzyme to assure that it is not kept 
in its inactive zymogen/inhibited form. 
Following the interesting results seen in the subcellular colocalization experiments, another 
organelle that would be fascinating to follow up on would be intracellular lysosomes. 
Lysosomes are important for removing cellular debris and are formed from endosomes 
generated by the Golgi apparatus. There is, thus, an integral link between the two organelles. 
Hypericin has been shown to colocalize with lysosomes in other cell types (Ali & Olivo, 
2002; Buytaert et al., 2006; Galanou et al., 2008; Kascakova et al., 2008; Siboni et al., 2002; 
Theodossiou et al., 2004) and the information gleaned from these further experiments would 
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provide a more complete picture of hypericin’s location is relation to all the major cellular 
organelles. 
This research will not only provide a solid foundation in hypericin’s use for PDR but may 
also uncover the molecular mechanism common to this therapy regardless of PS or light 
source used. However, caution should always be employed when extrapolating in vitro result 
to an in vivo application.  
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A. Appendix A 
A.1. Hoechst Staining Protocol 
Hoechst (Hoechst No. 33258 trihydrochloride ((2’-[4-hydroxyphenyl]-5-[4-methyl-1-
piperazinyl]-2,5’-bi-1H-benzimidazole) (Sigma-Aldrich, Schnelldorf, Germany) was used to 
stain the nucleus of cells and mycobacteria potentially present in the cells. Hoechst staining 
was done live or on fixed cells depending on the experiment. Hoechst powder was dissolved 
in distilled water for a stock solution with a concentration of 5mg/ml and stored at -20°C. 
The slides were viewed in the DAPI channel on a fluorescent microscope (Zeiss Axiovert 
200M fluorescent microscope, Carl Zeiss Microscopy GmbH, Germany) and in the infra-red 
range when the confocal microscope (Zeiss Axiovert 200M LSM 510 META Confocal 
microscope, Carl Zeiss Microscopy GmbH, Germany) was used. 
A.1.1. Live Cell staining 
A working stock of 0.5mg/ml Hoechst in water was used in all live cell experiments. At the 
end of each experiment the medium was replaced with complete medium with Hoechst 
diluted to 5µg/ml. The cells were exposed to Hoechst for 30 minutes at 37°C in the 
incubator. The Hoechst was discarded before the cells were washed thoroughly and 
incubated in fresh medium until viewing. 
A.1.2. Fixed Cell staining 
Cells were grown on coverslips for three days prior to staining. The dishes were washed 
with PBS and fixed with 1ml glacial acetic acid and methanol in a ratio of 1:3 for 6 minutes. 
The fixative was removed and the dishes were allowed to air dry. The cells were exposed to 
5ug/ml Hoechst solution for 6 minutes. The Hoechst was discarded and the multiple washes 
with PBS were done. The coverslips were lifted and mounted onto glass slides and left at 
room temperature until viewing. 
A.2. BCA protein quantification 
The BCA protein Assay kit (Thermo Scientific, Pierce, Rockford, IL, USA) is colorimetric 
assay where the peptide bond is reduced by copper ions present in the green working reagent 
provided in the kit. These ions are chelated by bicinchoninic acid (BCA) to create a purple 
solution. The samples were analysed on an ELISA plate reader at 562nm with a standard 
curve of known protein concentrations. To generate a standard curve, bovine serum albumin 
(BSA) was diluted with 0.9% saline to have a concentration of 2000µg/ml. This stock 
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solution was further diluted using incomplete RIPA buffer to known protein concentrations 
ranging from 0-2000µg/ml and 25µl to each well, of a 96-well plate, in duplicate.  
The protein lysates following protein extraction were diluted 5–fold using incomplete RIPA 
buffer and 25µl added per well in triplicate into the 96-well plate. The working reagent was 
prepared and 200µl added to each well. The solution was incubated at 37°C for 30 minutes 
in the dark as the working reagent is light sensitive. After 30 minutes the plate was cooled to 
room temperature and read at 562nm on a spectrophotometer plate reader. The standard 
curve used the absorbance values of the known protein concentrations and the two variables 
were plotted against one another. Following this, the unknown samples’ absorbance values 
were used with the standard curve to generate accurate protein concentrations and the 
average of the triplicates was reported and represented protein concentration as µg/µl. 
A.2.1. BCA Working Solution 
The number of wells was multiplied by 200µl and 50 parts of Reagent A to 1 part Reagent B 
was calculated for each experiment. An extra well was normally added to the calculation to 
account for pipetting error.  
A.2.2. Standard Protein Concentrations 
A stock solution of 2mg/ml BSA in saline was either supplied with the kit or made in the 
laboratory. For the standard curve of protein concentration, serial dilutions were performed 
from the stock solutions using the incomplete RIPA (Appendix A.4.1) as a diluent. The 
concentrations were: 2mg/ml, 1mg/ml, 500µg/ml, 250µg/ml, 125µg/ml and a blank with 
only incomplete RIPA buffer. 
A.3. Cell Culture Reagents 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
27.06g DMEM powder (Highveld Biological pty. Ltd. Johannesburg, South Africa)  
7.4g NaHCO3 
Make up to 1 litre with autoclaved double distilled water and adjust to pH 7.4 
Filter sterilize medium using 0.2µm filter into autoclaved bottles 
Store at 4°C 
A.3.1. Fetal Bovine Serum (FBS) 
Each 500ml of FBS (Highveld Biological pty. Ltd. Johannesburg, South Africa) was heat 
inactivated by 20 minute incubation in a 56°C water bath. It was allowed to cool and was 
aliquots were stored at -20°C until use. 
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A.3.2. Penicillin/Streptomycin 
Both antibiotics were combined to have a final concentration of 100U/ml of penicillin and 
100µg/ml of streptomycin sulphate salt in autoclaved distilled water. Stocks of penicillin and 
streptomycin were stored at -20°C. 
A.3.3. Trypsin/ethylenediaminetetraacetic acid (EDTA) 
0.05% trypsin and 0.02% EDTA are dissolved together in autoclaved PBS. The solution is 
sterilised through a 0.2µm filter and was stored at -20°C until use. 
A.4. RIPA Extraction Buffer 
A.4.1. Incomplete RIPA Buffer 
1.5ml of 50mM NaCl 
0.5ml Triton-X 100 
0.5ml 10% Sodium-Dodecyl Sulphate 
0.5 Tris-HCl pH 7.5 
0.5g Deoxycholate 
Make up to 50ml distilled water and adjust to pH 7.4 
Filter sterilize 
Store at 4°C 
A.4.2. Complete RIPA buffer 
40µl Roche Complete Protease Inhibitor Cocktail (X25) 
1µl 1mg/ml Aprotinin 
5µl 100mM PMSF 
1µl Pepstatin 
954µl incomplete RIPA buffer 
Add 50µl to a 35mm tissue plate 
A.5. Buffers 
A.5.1. Phosphate Buffered Saline X1 
8g NaCl 
0.2g KCl 
1.26g Na2HPO4 
0.2g KH2PO4 
Make up to 1 litre with autoclaved double distilled water and adjust to pH 7.4 
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A.6. XTT solution Reagents 
XTT solution was combined according to the manufacturers (Roche, Germany) instructions 
in subdued conditions. 
A.6.1. XTT Working Solution  
50µl Solution I 
1µl Solution II 
Solution I and II were combined in subdued light conditions. 
50µl was added to each well which contained 200µl medium. 
The solution I and II volumes were multiplied by the numbers of wells being treated and 
included another 0.5 well to account for pipetting error.  
A.7. DCF-DA solution 
The DCF-DA powder was dissolved in DMSO according to manufacturer’ (Sigma-Aldrich, 
Schnelldorf, Germany) instructions to a concentration of 100mM.  
A.7.1. DCF-DA working solution 
10µl 100mM DCF-DA solution  
990µl PBS 
Final concentration of DCF-DA in complete medium varied between 40µM and 10µM. 
A.8. Hypericin Uptake Assay photographs 
To confirm the fluorescent values from the uptake analysis (Section 3.1) microscopy was 
used to visualize hypericin within the fibroblast. Cells were seeded onto glass slides in 
35mm tissue culture dishes and each was incubated with the three hypericin concentration 
(0.25µM, 0.5µM and 1µM) for the same time course as uptake assay (2.5-24h) (Section 2.2). 
At the end of the time period images were taken of the tissue culture dish using the X10 lens 
on the Zeiss Axiovert 200M fluorescent microscope. The exposure time for hypericin 
detection set on the lowest hypericin concentration (0.25µM) and the shortest time (2.5h) for 
all the images. In this way, we could visually determine the amount of hypericin through its 
fluorescent intensity (Figure A.8.1). 
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Figure A.8.1 Photographs indicating the increase in fluorescent intensity in primary human 
fibroblasts over time and with increasing hypericin concentrations (A) 0.25µM, (B) 0.5µM and 
(C) 1µM. The same exposure time was kept all for the images. 
A 
B 
C 
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A.9. Maps of Plasmids Used in the Subcellular 
Localization Experiments 
A.9.1. Yellow Fluorescent Plasmid – Endoplasmic Reticulum  
The map below represents the plasmid used to visualise the ER. This plasmid was kindly 
donated by Georgia Schafer and Catherine Kaschula from the International Centre for 
Genetic Engineering and Biotechnology (ICGEB) and Department of Medical Biochemistry 
UCT. The plasmid design originated from Clontech (Catalog #6906, Clontech Laboratories, 
California, United States of America). 
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A.9.2. Green Fluorescent Protein - Golgi apparatus  
The map below represents the plasmid used to visualize the Golgi apparatus. The plasmid 
was designed by Choudhory et al and can be acquired from Addgene with the reference 
number:  Addgene plasmid 12605 (http://www.addgene.org/12605/) (Choudhury et al., 
2002). 
 
  
pEGFP-C1 V e ctor tnf o rm3tio n 
GenBank AccessiQn #: U55763 
EcoOl09 1 
'''''' 
GfP·HbrWT 
Stu] 
12'>711 
pEGFP·Cl 
4.7 kb 
Min 1111)(11 
111 11812) 
PT3028~5 
Catalog #6084-1 
Restr iction Map and MuUlp1e Clon ing Site (MCS) 01 pEGFP.Cl. All rMtriction sites mown are unique. The Xba I and 
Bel l siln (' ) are methylate-d ., the DNA PfoW:led by SO Bioscience-s Cionteth . II you wi$h 10 dige-s1 the veClor witIIlhes.e 
enzymes. you wi. need to Ir3nstorm the veclOi" ~o a d.:utr IIOS! :lII'I(! make Il'eSh DNA. 
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A.9.3. Green Fluorescent Protein – Mitochondria  
This map represents the plasmid used to visualise the mitochondria. The ornithine 
tricarboxylase was inserted into the MCS (Davids, 2003). The plasmid was generated in our 
laboratory with the parent plasmid being pEGFP-N1 (Catalog #6085-1) (BD Biosciences 
Clontech, United States of America).  
 
  
pEGFP-Nl Vector Information 
GenBank Accession #U55762 
EcoOl 09 1 
I~I 
ApaLI 
143621 '--~'-
Kan'l 
'00' 
pEGFP-Nl 
4.7kb 
PT3027-5 
Catalog #6085-1 
1113B'.11 
"'<'=C Nofl ll4Ol1 
Xba 1' 114121 
Afl II IH;4()1 
Re. triction ~3p and Mult iple Cloning Site (MCSI of pEGFP.Nl Vector. AI restriction sres shown are Ufliqlle . The Notl 
site follows the EGFP Slop codon . The Xbd I .He ('I is meth)'lated iflthe DNA provided b1 BO Bioscience, Clootech. "yoo 
lllish to dicJe.t the vectorwrth this enzyme, yoo wi~ nood to trans!oml the vector ifllO a d;)llf" arid make fresh DNA 
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A.10. Letter for Ethics Approval 
 
 
 
FACULTY OF HEALTH SCIENCES 
Humall Researeh Ethics OJmmll±ee 
List of documentation 
[PleaS<t see attached letter,] 
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Department of Human Biology 
Attention: Professor Marc Blockman 
Faculty of Health Sciences 'Research Ethics Committee 
1:52, ROOm 24 
Old Main Building 
Groote Schuur Hospital 
Faculty of Health Sci&r!C€s 
U;llVGrs.liy (If Cape Town 
OOSONO::::')' Cape 7925 
South Africa 
Tel: 4< 27 21 4066757 
Fax: + Z7 21 4487226 
June 2011 
Reques.t to Extend Protoco! : Regblitrv of Skin Samples fREe REF: 49312.009) 
Dear Prof Blockman and Committee Members 
Permission for the above-mentioned protocol ex;::lired November 2010. The projects 
associated with the Skin Registry are however ongoing through 2011~12 and include a 
current Masters and PhD proJect under my supervision. 11herefore request an extension of 
this protocol till the end of 2012. 
If you andlot your committee feel that a progress report is necessary to further substantiate 
this request, ! would gladly furnish you with one, 
Looking forward to your response, 
Regards. 
Dr Lester M. Davids, Principal Investigator 
Tel. 021·406 6787 
'~OL'R;'f[Ss'i(}"N i~ to ~ an (;'ll~t~:ld,ng teachii~g ami roswrc;, ,n;\vehity, 
",;iua.tir:g L,.f lJfe and :;.;ic.rcss.ing the ('hn1lenges facillil CJt ",,~dely.'· 
